UNITED STATES
SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, DC 20549

FORM 10-Q

QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the Quarterly Period Ended ~~March~~June 3130, 2012

TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from __________ to __________

Commission File No. ~~000-53750~~

000-53750

PROTEONOMIX, INC.

(Exact Name of Registrant As Specified In Its Charter)

Delaware

45-5185575

(State Or Other Jurisdiction Of
Incorporation Or Organization)

(I.R.S. Employer Identification No.)

~~145~~140 ~~Highview~~East ~~Terrace~~Ridgewood Avenue, ~~Hawthorne~~Suite 415, Paramus, NJ ~~07506~~07652

(Address of Principal Executive Offices and Zip Code)

Registrant’s Telephone Number, Including Area Code: (~~855~~973) ~~467~~949-~~7682~~4195

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ü No ___

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Website, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). Yes ___ No _X_

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer or a smaller reporting company. See definition of “large accelerated filer,” “accelerated filer,” and “smaller reporting company” in Rule 12b-2 of the Exchange Act.

Large Accelerated Filer [ ] Accelerated Filer [ ] Non-Accelerated Filer [ ] Smaller Reporting Company [ü]

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Act).

Yes __ No ü

The number of shares outstanding of the registrant’s common stock, as of ~~May~~August 120, 2012, was 7,~~885~~910,556.

NOTE REGARDING FORWARD-LOOKING STATEMENTS

Our disclosure and analysis in this Report contains forward-looking statements which provide our current expectations or forecasts of future events. Forward-looking statements in this Report include, without limitation:

information concerning possible or assumed future results of operations, trends in financial results and business plans, including those related to earnings, earnings growth, revenue and revenue growth;

statements about the level of our costs and operating expenses relative to our revenues, and about the expected composition of our revenues;

statements about expected future sales trends for our products;

statements about our future capital requirements and the sufficiency of our cash, cash equivalents, and available bank borrowings to meet these requirements;

information about the anticipated release dates of new products;

other statements about our plans, objectives, expectations and intentions;

and other statements that are not historical fact.

Forward-looking statements generally can be identified by the use of forward-looking terminology such as “believes,” “expects,” “may,” “will,” “intends, “plans,” “should,” “seeks,” “pro forma,” “anticipates,” “estimates,” “continues,” or other variations thereof (including their use in the negative), or by discussions of strategies, plans or intentions. Such statements include but are not limited to statements under Part I, Item 2 - Management’s Discussion and Analysis of Financial Condition and Results of Operations in this Report, and elsewhere in this Report. A number of factors could cause results to differ materially from those anticipated by such forward-looking statements, including those discussed under Part II, Item 1A - Risk Factors of this Report. The absence of these words does not necessarily mean that a statement is not forward-looking. Forward-looking statements are subject to known and unknown risks and uncertainties and are based on potentially inaccurate assumptions that could cause actual results to differ materially from those expected or implied by the forward-looking statements. Our actual results could differ materially from those anticipated in the forward-looking statements for many reasons, including factors described in Part II, Item 1A - Risk Factors of this Report. You should carefully consider the factors described in Part II, Item 1A - Risk Factors of this Report in evaluating our forward-looking statements.

You should not unduly rely on these forward-looking statements, which speak only as of the date of this Report. We undertake no obligation to publicly revise any forward-looking statement to reflect circumstances or events after the date of this Report, or to reflect the occurrence of unanticipated events. You should, however, review the factors and risks we describe in the reports we file from time to time with the Securities and Exchange Commission.

PROTEONOMIX, INC.

TABLE OF CONTENTS

PART I. FINANCIAL INFORMATION

ITEM 1. FINANCIAL STATEMENTS

Condensed Consolidated Balance Sheets

Condensed Consolidated Statements of Operations and Comprehensive Income (Loss)

Condensed Consolidated Statements of Cash Flows

Condensed Consolidated Statements of Changes in Stockholder’s Equity (Deficit)

Notes to Condensed Consolidated Financial Statements

ITEM 2. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION

AND RESULTS OF OPERATIONS

2622

ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISKS

3835

ITEM 4. CONTROLS AND PROCEDURES

3835

PART II. OTHER INFORMATION

3936

ITEM 1.

LEGAL PROCEEDINGS

3936

ITEM 1A.

RISK FACTORS

3937

ITEM 2.

UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS

4037

ITEM 3.

DEFAULTS UPON SENIOR SECURITIES AND CONVERTIBLE NOTES

4037

ITEM 4.

SUBMISSION OF MATTERS TO A VOTE OF SECURITY HOLDERS

4037

ITEM 5.

OTHER INFORMATION

4037

ITEM 6.

EXHIBITS

4037

SIGNATURES

4139

PART I. FINANCIAL INFORMATION

ITEM 1. FINANCIAL STATEMENTS

PROTEONOMIX, INC.
CONDENSED CONSOLIDATED BALANCE SHEETS
MARCH 31, 2012 (UNAUDITED) AND DECEMBER 31, 2011
JUNE 30, 2012 (UNAUDITED) AND DECEMBER 31, 2011
ASSETS	(UNAUDITED)
	MARCH 31,	DECEMBER 31,
	JUNE 30,	DECEMBER 31,
	2012	2011
Current Assets:
Cash and cash equivalents	$ 32,~~199~~398,~~455~~357	$ 13-
Accounts receivable, net	20,763	20,763
Inventory	-	-
Inventory	190,905	191,490
Prepaid expenses	385,000	18,000
Prepaid expenses	556,000	18,000
Current assets held under discontinued operations	-	212,266
Total Current Assets	32,~~967~~783,~~123~~357	230,266
Fixed assets, net of depreciation	2031,~~773~~885	22,779
Other Assets:
Intangible assets, net of amortization	~~260~~274,~~238~~193	253,050
Intellectual Property License, net of amortization	2,~~749~~664,~~862~~818	2,834,909
Total Other Assets	32,~~010~~939,~~100~~011	3,087,959
TOTAL ASSETS	$ 65,~~997~~754,~~996~~253	$ 3,341,004
LIABILITIES AND STOCKHOLDERS' EQUITY (DEFICIT)
LIABILITIES
Current Liabilities:
Obligation to issue common stock	$ 1,104,000	$ 1,104,000
Obligation to issue Series D Preferred stock	-	201,539
Current portion of notes payable - related parties	692,931	828,956
Derivative liability	405,052	-
Current portion of notes payable - related parties	599,154	828,956
Advance - related parties	1,500	-
Current portion of convertible note	1,~~630~~518,~~506~~256	1,548,500
Accounts payable and accrued expenses	32,~~212~~710,~~409~~490	3,~~355~~241,~~605~~661
Total Current Liabilities	6,641,346	7,038,600
Current liabilities held under discontinued operations	-	113,944
Total Liabilities	6,641,346	7,038,600
Total Current Liabilities	6,338,452	7,038,600
Total Liabilities	6,338,452	7,038,600
STOCKHOLDERS’ EQUITY (DEFICIT)
Preferred stock, $.001 Par Value; 10,000,000 shares authorized
Preferred stock Series A - 200,000 shares issued and outstanding	200	200
Preferred stock Series B - 6 shares issued and outstanding	-	-
Preferred stock Series C - 50,000 shares issued and outstanding	50	50
Preferred stock Series D - 344,000 and 0 shares issued and outstanding	344	-
Preferred stock Series E - 3,804 and 0 shares issued and outstanding	4	-
Common stock, $.001 Par Value; 240,000,000 shares authorized
and 7,885,556 and 7,685,556 shares issued and outstanding	7,886	7,686
and 7,910,556 and 7,685,556 shares issued and outstanding	7,911	7,686
Additional paid-in capital	2320,~~292~~558,~~228~~749	17,046,337
Accumulated deficit	(2221,~~944~~151,~~062~~457)	(20,751,869)
Total Stockholders’ Equity (Deficit)	~~356~~(584,~~650~~199)	(3,697,596)
TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY (DEFICIT)	$ 65,~~997~~754,~~996~~253	$ 3,341,004

PROTEONOMIX, INC.
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
FOR THE THREE MONTHS ENDED MARCH 31, 2012 AND 2011 (UNAUDUTED)
FOR THE SIX AND THREE MONTHS ENDED JUNE 30, 2012 AND 2011 (UNAUDUTED)
	THREE MONTHS ENDED
	SIX MONTHS ENDED		THREE MONTHS ENDED
	MARCH 31,
	JUNE 30,		JUNE 30,
	2012	2011	~~2011~~2012	2011
	(UNAUDITED)	(UNAUDITED)	(UNAUDITED)	(UNAUDITED)
OPERATING REVENUES
Sales	$ ~~2,290~~-	$ -	$ ~~8,165~~-	$ -
COST OF GOODS SOLD
Inventory - beginning	~~191,490~~-	-	~~187,299~~-	-
Purchases	-	-	~~3,287~~-	-
	191,490		190,586
	-	-	-	-
Inventory - end	~~(190,905)~~-	-	~~(187,207)~~-	-
Total Cost of Goods Sold	~~585~~-	-	~~3,379~~-	-
GROSS PROFIT	~~1,705~~-	-	~~4,786~~-	-
OPERATING EXPENSES
Wages and wage related expenses	95268,~~279~~985	131,354	66173,~~087~~706	65,267
Stock based compensation	-		-
Professional, consulting and marketing fees	2,297,020	65,237	312,015	13,758
Professional, consulting and marketing fees	1,997,005		79,779
Research and development	257,666	209,695	143,837	107,939
Other general and administrative expenses	32133,~~019~~910	76,070	4561,~~112~~588	42,098
Depreciation and amortization	9418,~~582~~955	19,189	939,~~905~~420	10,332
Total Operating Expenses	2,~~218~~976,~~885~~536	501,545	~~284~~700,~~883~~566	239,394
LOSS BEFORE OTHER INCOME (EXPENSE)	(2,~~217~~976,~~180~~536)	(501,545)	(~~280~~700,~~097~~566)	(239,394)
Forgiveness of payables	43838,~~812~~581	-	-794,768	-
Interest income (expense), net	(18,825)		(19,373)
Fair value of derivative liability	2,342,152	-	1,410,007	-
Total Other Income (expense)	24,987		(19,373)
Interest income (expense), net	(32,802)	(38,855)	(13,977)	(19,482)
NET LOSS BEFORE PROVISION FOR INCOME TAXES	(2,192,193)		(299,470)
Total Other Income (expense)	3,147,931	(38,855)	2,190,798	(19,482)
Provision for Income Taxes	-		(54)
NET INCOME (LOSS) BEFORE PROVISION FOR INCOME TAXES - CONTINUING OPERATIONS	171,395	(540,400)	1,490,232	(258,876)
NET LOSS APPLICABLE TO COMMON SHARES	$ (2,192,193)		$ (299,524)
Provision for Income Taxes	-	-	-	(54)
NET LOSS PER BASIC AND DILUTED SHARES	$ (0.28)		$ (0.06)
NET INCOME (LOSS) FROM CONTINUING OPERATIONS	171,395	(540,400)	1,490,232	(258,930)
WEIGHTED AVERAGE NUMBER OF COMMON
DISCONTINUED OPERATIONS
SHARES OUTSTANDING	7,805,886		5,365,706
Gain on disposal of subsidiary	10,424	-	10,424	-
Gain (loss) from discontinued operations	1,705	(33,270)	-	(15,308)
NET GAIN (LOSS) FROM DISCONTINUED OPERATIONS	12,129	(33,270)	10,424	(15,308)
NET INCOME (LOSS)	$ 183,524	$ (573,670)	$ 1,500,656	$ (274,238)
NET EARNINGS (LOSS) PER BASIC SHARES
From continuing operations	$ 0.02	$ (0.09)	$ 0.19	$ (0.04)
From discontinued operations	0.00	(0.01)	0.00	(0.00)
	$ 0.02	$ (0.10)	$ 0.19	$ (0.04)
NET EARNINGS (LOSS) PER DILUTED SHARES
From continuing operations	$ 0.02	$ (0.09)	$ 0.07	$ (0.04)
From discontinued operations	0.00	(0.01)	0.00	(0.00)
	$ 0.02	$ (0.10)	$ 0.07	$ (0.04)
WEIGHTED AVERAGE NUMBER OF COMMON
SHARES OUTSTANDING (BASIC)	7,846,957	5,832,592	7,888,029	6,294,347
WEIGHTED AVERAGE NUMBER OF COMMON
SHARES OUTSTANDING (DILUTED)	7,846,957	5,832,592	20,305,161	6,294,347

PROTEONOMIX, INC.
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
FOR THE THREE MONTHS ENDED MARCH 31, 2012 AND 2011 (UNAUDITED)
FOR THE SIX MONTHS ENDED JUNE 30, 2012 AND 2011 (UNAUDITED)
		THREE MONTHS ENDED
	SIX MONTHS ENDED
		MARCH 31,
	JUNE 30,
	2012	~~2012~~2011	~~2011~~
	(UNAUDITED)	(UNAUDITED)	~~(UNAUDITED)~~
CASH FLOWS FROM OPERATING ACTIVITIES
CASH FLOWS FROM OPERATING ACTIVITIES - CONTINUING ACTIVITIES
Net loss		$ (2,192,193)	$ (299,524)
Net income (loss)	$ 183,524	$ (540,400)
Adjustments to reconcile net loss to net cash
used in operating activities:
provided by (used in) operating activities:
Depreciation and amortization		94,582	93,905
Depreciation and amortization including amortization in research and development costs	189,050	189,284
Consulting services rendered for convertible note	82,006	~~82,006~~-	-
Common stock issued for consulting services and prepaid expenses	253,250	~~239~~20,~~500~~600	~~14,600~~
Preferred warrants issued to placement agent	1,293,509	~~1,293,509~~-	-
Forgiveness of payables		(43,812)	-
Fair value adjustment on derivative liability	(2,342,152)	-
Obligation to issue common shares - services		-	-
Forgiveness of payables	-	-
Obligation to issue Series D Preferred shares - services		-	-
Obligation to issue common shares - services	-	-
Changes in assets and liabilities
Obligation to issue Series D Preferred shares - services		-
(Increase) decrease in accounts receivable		-	(5,184)
Changes in assets and liabilities
(Increase) decrease in inventory		585	92
(Increase) decrease in accounts receivable	20,763	-
Decrease in prepaid expenses		122,000	-
(Increase) decrease in inventory	191,490	-
Increase (decrease) in accounts payable and
Decrease in prepaid expenses	(293,000)	-
and accrued expenses		(99,384)	169,559
Increase in derivative liability	405,052
Total adjustments		1,688,986	272,972
Increase (decrease) in accounts payable and
Net cash (used in) operating activities		(503,207)	(26,552)
and accrued expenses	(1,048,998)	499,192
CASH FLOWS FROM FINANCING ACTIVITES
Total adjustments	(1,249,030)	709,076
Increase in patent fees		(14,717)	(9,560)
Net cash provided by (used in) operating activities	(1,065,506)	168,676
Net cash (used in) investing activities		(14,717)	(9,560)
CASH FLOWS FROM INVESTING ACTIVITES
CASH FLOWS FROM FINANCING ACTIVITES
Acquisition of equipment	(12,635)	-
Proceeds received from private placement		3,751,891	-
Increase in patent fees	(36,569)	(9,560)
Proceeds (repayment) from notes payable - related parties		(36,025)	37,019
Net cash (used in) investing activities	(49,204)	(9,560)
Advance from related party		1,500	-
CASH FLOWS FROM FINANCING ACTIVITES
Net cash provided by financing activities		3,717,366	37,019
Proceeds received from private placement	3,751,891	-
NET INCREASE (DECREASE) IN
Proceeds (repayment) from convertible notes payable	(112,250)	-
CASH AND CASH EQUIVALENTS		3,199,442	907
Proceeds (repayment) from notes payable - related parties	(129,792)	82,233
CASH AND CASH EQUIVALENTS -
Advance from related party	1,500	-
BEGINNING OF PERIOD		13	18
Net cash provided by financing activities	3,511,349	82,233
CASH AND CASH EQUIVALENTS - END OF PERIOD		$ 3,199,455	$ 925
DISCONTINUED OPERATIONS
CASH PAID DURING THE YEAR FOR:
Operating activities	1,705	(240,853)
Income taxes		$ -	$ -
Investing activities	-	-
Interest expense		$ -	$ -
Financing activities	-	-
SUPPLEMENTAL NONCASH INFORMATION:
	1,705	(240,853)
Common stock issued for consulting services		$ -	$ 14,600
NET INCREASE (DECREASE) IN
Conversion of notes payable and accrued interest for common stock
CASH AND CASH EQUIVALENTS	2,398,344	496
and additional paid in capital		$ -	$ 450,000
CASH AND CASH EQUIVALENTS -
Deferred financing fees recorded for issuance of warrants		$ 256,762	$ -
BEGINNING OF PERIOD	13	18
Issuance of Series D Preferred Stock for Obligation to issue Series D Preferred shares		$ 201,539	$ -
CASH AND CASH EQUIVALENTS - END OF PERIOD	$ 2,398,357	$ 514
Issuance of Series D Preferred Stock in conversion of convertible note		$ 100,000	$ -
CASH PAID DURING THE YEAR FOR:
Common stock issued for prepaid consulting services		$ 660,000	$ -
Income taxes	$ -	$ -
Consulting services rendered for convertible note		$ 82,006	$ -
Interest expense	$ -	$ -
SUPPLEMENTAL NONCASH INFORMATION:
Common stock issued for consulting services	$ 253,250	$ 20,600
Conversion of notes payable and accrued interest for common stock
and additional paid in capital	$ -	$ 515,000
Deferred financing fees recorded for issuance of warrants	$ 256,762	$ -
Stock options issued for the license	$ -	$ -
Conversion of obligation to issue common shares to convertible note	$ -	$ -
Conversion of obligation to issue common shares to obligation to issue
Series D Preferred shares	$ -	$ -
Issuance of Series D Preferred Stock for Obligation to issue Series D Preferred shares	$ 201,539	$ -
Issuance of Series D Preferred Stock in conversion of convertible note	$ 100,000	$ -
Common stock issued for prepaid consulting services	$ 660,000	$ 48,000
Consulting services rendered for convertible note	$ 82,006	$ -

PROTEONOMIX, INC.

CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDER’S EQUITY (DEFICIT)

FOR THE YEARS ENDED DECEMBER 31, 2011 AND 2012

Additional Retained

Preferred Stock A Preferred Stock B Preferred Stock C Preferred Stock D Preferred Stock E Common Stock Paid-in Earnings

Shares Amount Shares Amount Shares Amount Shares Amount Shares Amount Share Amount Capital (Deficit) Total

Balance December 200,000 $200 6 $ - 50,000 $ 50 - $ - - $ - 5,161,984 $5,162 $15,919,761 $(19,368,023) $(3,422,850)

31, 2010

Shares issued for - - - - - - - - - - 1,500,000 1,500 590,000 - 591,500

Conversion of

convertible note

Shares issued for - - - - - - - - - - 803,572 804 449,196 - 450,000

conversion of note

payable-related parties

Shares issued for - - - - - - - - - - 220,000 220 87,380 - 87,600

services (and

Prepaid expenses)

Net loss for the year - - - - - - - - - - - - - (1,383,846) (1,383,846)

Ended December 31

2011

Balance December 200,000 200 6 - 50,000 50 - - - - 7,685,556 7,686 17,046,337 (20,751,869) (3,697,596)

31, 2011

Series D Preferred - - - - - - 344,000 344 - - - - 301,195 - 301,539

Shares Issued for

liability of stock

To be issued

Series E Preferred - - - - - - - 3,804 4 - - (3,751,887) - (3,751,891)

Shares Issued in

private placement

Shares of common - - - - - - - - - - 200,000 200 899,300 - 899,500

Stock Issued for

services rendered

And prepaid services

Value of preferred - - - - - - - - - - - - 1,293,509 - 1,293,509

warrants Issued in

private placement

To placement agent

Net loss for the three - - - - - - - - - - - - - (2,192,193) (2,192,193)

Months Ended March

31, 2012

200,000 200 6 - 50,000 50 344,000 344 3,804 4 7,885,556 7,886 23,292,228 (22,944,062) 356,650

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(Unaudited)

NOTE 1 -ORGANIZATION AND BASIS OF PRESENTATION

The unaudited financial statements included herein have been prepared, without audit, pursuant to the rules and regulations of the Securities and Exchange Commission (“SEC”). The financial statements and notes are presented as permitted on Form 10-Q and do not contain information included in the Company’s annual statements and notes. Certain information and footnote disclosure normally included in financial statements prepared in accordance with accounting principles generally accepted in the United States of America have been condensed or omitted pursuant to such rules and regulations, although the Company believes that the disclosures are adequate to make the information presented not misleading. It is suggested that these financial statements be read in conjunction with the December 31, 2011 Form 10-K filed with the SEC, including the audited financial statements and the accompanying notes thereto. While management believes the procedures followed in preparing these financial statements are reasonable, the accuracy of the amounts are in some respects dependent upon the facts that will exist, and procedures that will be accomplished by the Company later in the year.

These unaudited financial statements reflect all adjustments, including normal recurring adjustments which, in the opinion of management, are necessary to present fairly the operations and cash flows for the periods presented.

Proteonomix, Inc. (the “Company") is a Delaware corporation incorporated on June 26, 1995 as Azurel, Ltd. In September 2006, Azurel, Ltd. changed its name to National Stem Cell Holding, Inc. and then in August 2008 the name of the Company was changed to Proteonomix, Inc.

~~The~~Prior to April 30, 2012, the Company ~~owns~~owned and ~~operates~~operated seven subsidiaries, The Sperm Bank of New York, Inc., Proteoderm, Inc., National Stem Cell, Inc., PRTMI, StromaCel, Inc., XGen ~~Medical~~, LLC, and Thor Biopharma. On April 30, 2012, the Company disposed of its lone operating subsidiary, The Sperm Bank of New York, Inc. The sale resulted in a gain of $10,424, which represented the net value of the net assets as of April 30, 2012. There was no activity in this subsidiary during the month of April, and the Company entered into the development stage as of April 1, 2012 while they further their research and development of their core technology.

The Company is a biotechnology company engaged in the discovery and development of ~~stem~~ cell therapeutic products. The Company is developing pre-clinical-stage therapeutic agents and treatments for cancer, diabetes, heart, lung, and kidney diseases as well as for ~~stem cell~~ bone marrow and organ transplants. The Company’s discoveries involve ~~stem~~ cell treatments ~~without using embryonic stem cells~~.

~~Azurel, Ltd~~. was incorporated on June 26, 1995 in the State of Delaware and marketed a line of fragrances. On February 2, 2001, Azurel filed a voluntary petition for protection from creditors under Chapter 11 in the United States Bankruptcy Court for the District of New Jersey, Newark until it was discharged from bankruptcy in December, 2005. Control was changed in September 2006 when Azurel acquired National Stem Cell, Inc. and its subsidiary, The Sperm Bank of New York, Inc. through a share exchange agreement. In this transaction the common stock was reverse split 1:37. Azurel subsequently changed its name following the acquisition. Then again in August 2008, the Company reverse split its stock 1:10 when the name was changed to Proteonomix, Inc.

On ~~January~~June 1418, ~~2005~~2012, ~~National~~the ~~Stem~~Company ~~Cell,~~entered ~~Inc.~~into ~~acquired~~an ~~The~~Exclusive ~~Sperm~~License ~~Bank~~Agreement ofwith ~~New~~Ian ~~York~~McNiece, ~~Inc.~~the aCompany’s ~~company~~Chief ~~established~~Scientific inOfficer ~~1997~~(the ~~operating as a reproductive cell and tissue bank~~“Licensor”). ~~National~~Under ~~Stem~~the ~~Cell,~~terms ~~Inc. acquired The Sperm Bank~~ of ~~New~~the ~~York,~~Exclusive ~~from~~License ~~its sole shareholder~~Agreement, ~~for~~the aLicensor ~~note~~hereby ~~payable~~grants into the ~~amount~~Company ofan ~~$150~~exclusive,~~000~~ ~~and acquired the accounts receivable and inventory valued at $150~~worldwide,~~000.~~ Onroyalty ~~January~~bearing 13license, ~~2006,~~with ~~National~~the ~~Stem~~right ~~Cell~~to ~~Inc.~~grant ~~converted~~sublicenses to the ~~note~~Technology, ~~payable~~Licensed ~~into 21~~Products,~~866~~ ~~shares~~Licensed ofImprovements ~~common~~and ~~stock.~~Patents ~~The acquisition was treated~~ as anoted ~~purchase~~in ~~transaction~~the agreement.

OnThe ~~July~~Company 8,will ~~2008,~~pay the ~~Company~~Licensor ~~formed~~the ~~Proteoderm~~amounts set forth herein upon the first occurrence of each of the following milestone events: (1) License fee (upon execution of the agreement) - $100,000; ~~Inc.~~(2) asAgreement with a ~~wholly-owned~~third ~~subsidiary.~~party ~~Through~~related to this ~~subsidiary~~technology - $250,000 and 50,000 shares of common stock; (3) Successful patent issue - $50,000; (4) Isolation of the ~~Company~~active ~~produces~~factor ~~and~~for ~~synthesizes~~tumor ~~protein~~inhibition ~~polypeptides~~- ~~and~~$50,000; ~~growth~~(5) ~~hormone~~Initiation ~~secreted~~of bythe ~~stem~~Phase ~~cells~~I clinical trial of the Licensed Products - $100,000; and ~~incorporates~~(6) ~~them~~Grant ~~into~~by ~~uniquely~~or ~~formulated~~marketing ~~personal~~approval ~~care~~of ~~products.~~the ~~Proteoderm,~~Licensed ~~Inc.~~Product ~~has~~in ~~generated~~the noUS ~~revenues~~(FDA) ~~since~~or ~~inception~~Europe - $500,000. The license fee due upon execution was paid on June 18, 2012.

OnUpon ~~January~~the 5,First ~~2010~~Commercial Sale of Licensed Product, the Company ~~formed~~shall pay to the ~~Proteonomix~~Licensor ~~Regenerative~~a ~~Translational~~royalty ~~Medicine~~of ~~Institute,~~three percent (~~“PRTMI”~~3%), asof aNet ~~wholly-owned~~Sales ~~subsidiary.~~of ~~PRTMI~~a ~~will~~Licensed ~~focus~~Product onduring the ~~translation~~Royalty ofTerm, ~~research~~as indescribed ~~stem~~therein. ~~cell~~In ~~biology~~addition, ~~and~~the ~~cellular~~Company ~~therapy~~shall pay to ~~clinical~~Licensor ~~applications~~an ofamount ~~regenerative~~equal ~~medicine. PRTMI~~to ~~formed~~three ~~PRTMI~~percent ~~RD,~~(3%) aof ~~company incorporated in~~ the ~~Dominican~~Sublicense ~~Republic~~Fee inreceived ~~February,~~from ~~2010~~any Sublicense.

On February 24, 2010 the Company acquired StromaCel, Inc., a wholly-owned subsidiary for the price of its formation cost on December 24, 2009. The mission of StromaCel is to develop therapies using stromal cells. Stromal cells are key components of tissues and provide critical cytokines and growth factors as well as the cellular microenvironment for normal homeostasis.

On May 4, 2010, Proteonomix licensed from the Cohen-McNiece Foundation the Stromal Cell technology for potential therapeutic use in the regrowth of damaged cardiac cells after a heart attack. The Cohen-McNiece Foundation was formed by Proteonomix President, Michael Cohen, and its Chief Scientific Officer and Vice-President, Ian McNiece, PhD to develop cellular technology for patients who have suffered myocardial infarctions. The Technology was licensed in exchange for a 2% royalty on gross revenue derived from use of the StromalCel Technology and 1,000,000 stock options exercisable for five years at $3.55 per share vested immediately to Michael Cohen, our President and 90% owner of the Cohen-McNiece Foundation. The 2% royalty will be used by the Foundation to do further research into stem cell applications. Proteonomix also received a right of first refusal to license any technology developed by the Foundation.

Proteonomix has sub-licensed the StromaCel Technology to StromaCel for a 2% royalty, but Proteonomix will remain responsible for all costs associated with patent prosecution for the StromaCel Technology. In the event of bankruptcy, the rights to the Technology granted by the license revert to the Foundation.

On August 6, 2010 the Company formed a new subsidiary XGen Medical LLC, a Nevis Islands entity (“XGen Medical” or “XGen”). XGen Medical has been established with the intention of conducting business in the global medical marketplace. Proteonomix plans on utilizing XGen Medical to serve as a platform for joint ventures with medical facilities worldwide. It was anticipated that new relationships formed with XGen Medical will create medical facilities capable of not just attracting treatments locally, but also acting as hubs for medical tourism. The establishment of a separate subsidiary, XGen Medical LLC., was useful in order to allow Proteonomix to properly enter global markets with the intention of soliciting business through our proprietary PRTMI model. Under an agreement, two investors were responsible for investing $5,000,000 into XGen Medical in exchange for a 49% interest in XGen Medical. In exchange for the investment StromaCel was to provide XGen Medical with the technology to practice the cardiac treatment utilizing the technology, and Proteoderm granted distribution rights to cosmeceuticals containing the proprietary stromal cell cosmetic technology in the GCC countries. Due to a default by one of the investors, the remaining investor has indicated that payments toward satisfaction of the contract will be made. To the date of this filing no such payments have been made. The Company plans on litigating to the fullest extent of the law to collect this investment along with any penalties incurred in the default. The negotiations with the second investor failed and the counterparties to the XGen Medical Agreements breached their contract responsibilities. We have assumed one hundred percent (100%) ownership of XGen Medical and are contemplating legal actions against both Patrizio Shawal Pilati and Valentina Earp-Jones, the counterparties to the XGen Medical Agreement. The minority shareholders that are in default will be pursued by all legal means.

In January, 2011, Ian McNiece joined the Company’s Board of Directors, and the Company formed Thor BioPharma, Inc. as a wholly owned subsidiary to exploit the Company’s UMK-121 Technology related to stem cells that were licensed during the same month from the Cohen McNiece Foundation. The management of the Company will divert resources to Thor Biopharma as the need may arise.

On January 3, 2011 the Company formed a new subsidiary, THOR BioPharma, Inc., in order to provide an entry into the pharmaceutical market. On March 2, 2011, The Company entered into an agreement with The Cohen McNiece Foundation, Inc. (the "Foundation"), a Florida not-for-profit corporation, to exclusively develop and license the Foundation's UMK-121 Mobilization of Bone marrow Stem Cell technology ("UMK-121") which is a proprietary technology based upon existing FDA approved drugs. The License imposes no upfront costs on the Issuer which will sublicense UMK-121 to its wholly owned subsidiary THOR BioPharma. The Company is required to make milestone payments to the Foundation upon 1) the issuance of a patent, 2) completion of Phase III trials and 3) commercialization which will require the payment of a 3% royalty on net sales. On April 7, 2011, the Company announced that it had filed a provisional patent application in anticipation of commencement of its initial clinical trial of a drug combination thought to extend life expectancy for a class of terminally ill patients awaiting liver transplants. The Company, based upon its exclusive license agreement to develop Mobilization of Bone Marrow Stem Cells Technology (UMK-121), filed a patent application in April 2011, covering mobilization of non-hematopoietic stem cells for applications in regenerative medicine.

On February 1, 2011, the Company filed an additional patent application to improve the Company's patent position on StromaCel with respect to a newly developed breakthrough method of stem cell expansion. This new methodology is used to mass-produce stem cells for therapeutic use once the stem cell line has been selected and purified. The Company believes that the new process application will dramatically expand product availability and reduce the cost of production of StromaCel to the Company and patient. The Company also believes that the technology presented in the new patent application will allow it to move to a new clinical trial quickly for the StromaCel product. Furthermore, the Company believes that this expansion model will be applicable to a wide range of stem cell technologies, providing further trials and potential revenue streams to the Company.

On February 1, 2011, the Company filed a Registration Statement on Form S-1 covering an exchange proposal whereby shareholders would exchange their common stock for convertible preferred stock that would allow the holder to convert their preferred stock into 1.3 times as many common shares by paying a declining conversion price and ultimately converting their common shares after three years at no additional price. Management believes that this transaction will not impact our business model nor our scientific research in the long term. The Company received a brief comment letter from the SEC staff requesting the filing of a Form TO and general modification of the filing to comply with exchange and/or tender offer disclosure. However, since the receipt of that comment, the Company has decided to significantly amend its registration statement to drop the exchange offer and proceed with a private placement of common stock and warrants.

On July 27, 2011, the Company and Gilford Securities, Inc. (“Gilford”) of New York, NY signed a Letter of Engagement whereby Gilford undertakes to act as a dealer on a best efforts basis in a proposed public offering of the Company’s securities. Gilford is to receive a refundable grant of 325,000 shares of the Company’s common stock, and 8% of the cash proceeds for the first $5,000,000 of gross proceeds raised by Gilford and 10% cash for any sums raised by Gilford in excess of $5,000,000. In addition Gilford is to receive seven year warrants equal to 8% of the securities sold up to $5,000,000 and equal to 10% of the securities in excess of $5,000,000 all exercisable at the public offering price. Gilford also would be compensated for any private funds raised or any merger and acquisition work performed. Gilford also has the right to act as the syndicate manager in its sole discretion.

On November 11, 2011, the Company announced that that the Cosmetic Ingredients Review Board (“CIR”) had approved and assigned an INCI nomenclature to its innovative Matrix NC-138 Cosmeceutical product, a necessary final step prior to manufacturing and commercialization of cosmetic products in the United States.

On November 15, 2011, the Company entered into an agreement with the University of Miami, to conduct an FDA human clinical trial, in patients afflicted with End Stage Liver Disease, of the Issuer’s UMK-121 Biopharmaceutical Stem Cell Technology, which is a proprietary technology, based upon existing FDA approved drugs. The Issuer sublicensed UMK-121 to its wholly owned subsidiary THOR BioPharma. The Issuer is required to pay $105,000 to the University and the University will absorb all other costs associated with the study. The Company has agreed to pay a 3% net royalty to the University in the event of commercialization of UMK-121. On December 27, 2011, the Company announced that it had completed payment of the $105,000 to the University. On April 10, 2012, the University of Miami terminated the Research Agreement between the University and the Company by delivering written notice of the termination to the Company. The $105,000 that was paid by the Company was returned. The Company is currently interviewing other institutions to conduct this trial.

On December 29, 2011, The Series A1 and Series C Preferred Stock classes were amended. The primary effect of the amendment was to protect existing Class A1 and Class C Convertible Preferred Stock conversion rights against dilution in most circumstances, including reverse splits in the common stock and to add conversion to the Series C at a rate of 100 common shares for each share of Series C Preferred Stock converted. Also on December 29, 2011, Proteonomix, Inc. (the “Company”) created a new class of securities, the Class D Preferred Stock The primary terms of the Class D Preferred is that in addition to preferences upon liquidation, the Class D is convertible at a ratio 10 common shares to 1 converted Class D Preferred share of the Company. In addition, the Class D conversion rights are protected against dilution in most circumstances, including reverse splits in the common stock.

Going Concern

. During the ~~three~~six-month period ended ~~March~~June 3130, 2012, the Company’s ~~revenue~~spent ~~generating~~most ~~activities~~of ~~consisting~~their ~~solely~~time offurthering the ~~sperm~~research ~~bank~~and ~~activities~~development ~~have~~of their core technology. The Company has not produced sufficient funds for profitable operations and have incurred significant operating losses since inception. In view of these matters, realization of certain of the assets in the accompanying consolidated balance sheet is dependent upon continued operations, which in turn is dependent upon our ability to meet our financial requirements, raise additional financing on acceptable terms, and the success of future operations. We anticipate revenues to commence on our cosmeceutical products by the end of 2012 on these products. We have outstanding trade and accrued payables of $32,~~212~~127,~~409~~378 including accrued salaries due to our management of, $1,~~701~~732,~~667~~500, and loans from our Chief Executive Officer’s of $~~629~~588,~~297~~797.

As shown in the accompanying condensed consolidated financial statements the Company has incurred recurring losses of $2,192,193 and $299,524 for the three months ended March 31, 2012 and 2011 respectively. In addition, the Company has a working capital deficit in the amount of $2,674,223 as of March 31, 2012. The Company has continued to develop its pre-clinical-stage therapeutic agents and various treatments utilizing stem cell treatments while generating revenues and operating its sperm bank division. 7

As shown in the accompanying condensed consolidated financial statements the Company has incurred recurring losses from operations aggregating $2,976,536 and $501,545 for the six months ended June 30, 2012 and 2011 respectively. In addition, the Company has a working capital deficit in the amount of $2,971,983 as of June 30, 2012. The Company has continued to develop its pre-clinical-stage therapeutic agents and various treatments utilizing stem cell treatments. For the six months ended June 30, 2012 , the Company also reduced accounts payables by $838,581, recognized a Fair value of derivative liability aggregating $2,342,152, interest income net aggregated $32,802 and the Company had a gain from discontinued operations of $12,129 for a net income of $183,524.

Our independent registered public accounting firm’s report on the consolidated financial statements included in our annual report on Form 10-K for the year ended December 31, 2011, contains an explanatory paragraph wherein they expressed an opinion that there is substantial doubt about our ability to continue as a going concern. Accordingly, careful consideration of such opinions should be given in determining whether to continue or become our stockholder.

We are currently spending or incurring (and accruing) expenses of approximately $180,000 per month on operations and the continued research and development of our technologies and products. Management believes that we will require approximately an additional $3,000,000 to fund our operations for the next 12 months and to repay certain outstanding trade payables and accrued expenses. In December 2011, the Company received $150,000 in the form of a convertible note. The proceeds of this note went to pay for the Company’s share to fund the Company’s $105,000 commitment to the University of Miami, which was returned on April 10, 2012, for the clinical trial to be conducted by the University of Miami, and to pay for certain accrued professional fees and director and officer insurance coverage. This trial was terminated by the University in April, 2012. The Company is continuing to seek a new facility to conduct the trial.

WeOn ~~are~~March ~~currently~~5, ~~spending~~2012, orthe ~~incurring~~Company entered into a Securities Purchase Agreement (~~and~~the ~~accruing~~“SPA”) ~~expenses~~with ofthe ~~approximately~~purchasers ~~$100~~identified therein (collectively,~~000~~ ~~per~~the ~~month~~“Purchasers”) onproviding ~~operations~~for the issuance and sale by the ~~continued~~Company ~~research~~to ~~and~~the ~~development~~Purchasers of ~~our~~an ~~technologies~~aggregate ~~and~~of ~~products. Management~~approximately ~~believes~~3,804 ~~that~~shares weof ~~will~~the ~~require~~Company’s ~~approximately~~newly andesignated ~~additional~~Series $2E Convertible Preferred Stock,~~100,000~~ towith ~~fund~~each ~~our~~of ~~operations~~the ~~for~~Series E Convertible Preferred shares initially convertible into approximately 235 shares of the ~~next~~Company’s 12common ~~months~~stock (the “Conversion Shares”) and tothree ~~repay~~series ~~certain~~of ~~outstanding~~warrants, ~~trade~~the ~~payables~~Series A Warrants, the Series B Warrants and ~~accrued~~the ~~expenses.~~Series InC ~~December~~Warrants, ~~2011~~to purchase up to an aggregate of 2,685,873 shares of the Company’s ~~received~~common ~~$150~~stock,~~000~~ infor proceeds to the ~~form~~Company of a$3.8 ~~convertible note~~million. ~~The~~After deducting fees and expenses, the aggregate net proceeds from the sale of ~~this~~the ~~note~~Preferred ~~went~~Shares toand ~~pay~~associated ~~for~~warrants are approximately $3.5 million. Rodman & Renshaw, LLC (“Rodman”) acted as the ~~Company’s~~exclusive ~~share~~placement toagent ~~fund~~for the ~~Company’s~~private ~~$105,000~~placement. ~~commitment~~Pursuant to the ~~University~~terms of ~~Miami,~~the ~~which~~Placement ~~was~~Agent ~~returned~~Agreement entered into by the Company and Rodman on ~~April~~February 1015, 2012, ~~for~~(the “Placement Agent Agreement”). In accordance with the ~~clinical~~Placement ~~trial~~Agent toAgreement, bethe ~~conducted~~placement byagent received as a fee, cash in the ~~University~~amount of ~~Miami~~$267,249 and a Series E Preferred Stock Purchase Warrant, enabling the placement agent to ~~pay~~subscribe for ~~certain~~and ~~accrued~~purchase ~~professional~~from ~~fees~~the Company up to 266.3494 shares of Series E Preferred Stock, and ~~director~~62,670 of each of the Series A, B and ~~officer~~C ~~insurance~~Common ~~coverage~~Stock Warrants. ~~The~~This ~~Company~~Series isE ~~currently~~Preferred ~~interviewing~~Stock ~~other~~Purchase ~~institutions~~Warrant towas ~~conduct~~valued ~~this~~at ~~trial~~$1,293,509, and has been expensed during 2012.

On March 5, 2012, the Company entered into a Securities Purchase Agreement (the “SPA”) with the purchasers identified therein (collectively, the “Purchasers”) providing for the issuance and sale by the Company to the Purchasers of an aggregate of approximately 3,804 shares of the Company’s newly designated Series E Convertible Preferred Stock, with each of the Series E Convertible Preferred shares initially convertible into approximately 235 shares of the Company’s common stock (the “Conversion Shares”) and three series of warrants, the Series A Warrants, the Series B Warrants and the Series C Warrants, to purchase up to an aggregate of 2,685,873 shares of the Company’s common stock, for proceeds to the Company of $3.8 million. After deducting fees and expenses, the aggregate net proceeds from the sale of the Preferred Shares and associated warrants are approximately $3.5 million. Rodman & Renshaw, LLC (“Rodman”) acted as the exclusive placement agent for the private placement. Pursuant to the terms of the Placement Agent Agreement entered into by the Company and Rodman on February 15, 2012 (the “Placement Agent Agreement”). In accordance with the Placement Agent Agreement, the placement agent received as a fee, cash in the amount of $267,249 and a Series E Preferred Stock Purchase Warrant, enabling the placement agent to subscribe for and purchase from the Company up to 266.3494 shares of Series E Preferred Stock, and 62,670 of each of the Series A, B and C Common Stock Warrants. This Series E Preferred Stock Purchase Warrant was valued at $1,293,509, and has been expensed in the three months ended March 31, 2012.

There is no guarantee that the Company will be able to raise enough capital or generate revenues to sustain its operations. These conditions raise substantial doubt about the Company’s ability to continue as a going concern for a reasonable period. Management believes that the Company’s capital requirements will depend on many factors. These factors include the final phase of development of their pre-clinical stage therapeutic agents being successful as well as product implementation and distribution.

The condensed consolidated financial statements do not include any adjustments relating to the carrying amounts of recorded assets or the carrying amounts and classification of recorded liabilities that may be required should the Company be unable to continue as a going concern.

NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

Principles of Consolidation

The condensed consolidated financial statements include the accounts of the Company and its subsidiaries. All significant intercompany accounts and transactions have been eliminated in consolidation.

Use of Estimates

The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. On an ongoing basis, the Company evaluates its estimates, including, but not limited to, those related to derivative liabilities, bad debts, income taxes and contingencies. The Company bases its estimates on historical experience and on various other assumptions that are believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying value of assets and liabilities that are not readily apparent from other sources. Actual results could differ from those estimates.

Cash and Cash Equivalents

The Company considers all highly liquid debt instruments and other short-term investments with an initial maturity of six months or less to be cash equivalents. Any amounts of cash in financial institutions over FDIC insured limits, exposes the Company to cash concentration risk.

Fair Value of Financial Instruments (other than Derivative Financial Instruments)

The carrying amounts reported in the condensed consolidated balance sheets for cash and cash equivalents, and accounts payable approximate fair value because of the immediate or short-term maturity of these financial instruments. For the notes payable, the carrying amount reported is based upon the incremental borrowing rates otherwise available to the Company for similar borrowings.

Research and Development

The Company incurs costs on activities that relate to research and development of new technology and products. Research and development costs are expensed as incurred. Certain of these costs may be reduced by government grants and investment tax credits where applicable. The Company has never had any government grants or investment tax credits. Or the six months ended June 30, 2012 and 2011, the Company has an aggregate of $257,666 and $209,695 respectively.

Intangible Assets

The Company’s intangible assets consist of patents and intellectual property, which are carried at the purchase price and/or the legal cost to obtain them. Patents are being amortized over their estimated useful lives, which range from seven to seventeen years. The cost of intellectual property purchased from others that is immediately marketable or that has an alternative future use is capitalized and amortized as intangible assets. Capitalized costs are amortized using the straight-line method over the estimated economic life of the related asset. The Company periodically reviews its capitalized intangible assets to assess recoverability based on the projected undiscounted cash flows from operations, and impairments are recognized in operating results when a permanent diminution in value occurs.

The value assigned to the license is being amortized over a ten-year life. The Company will test for impairment on an annual basis and impair the value if necessary.

Revenue Recognition

The Company ~~recognizes~~when they had sperm bank operations recognized revenue for the sales of its donor sperm samples, ~~which have been the only source of revenue to date are~~ when persuasive evidence of an arrangement exists and delivery has occurred, provided the fee is fixed or determinable and collection iswas probable. The Company ~~assesses~~assessed whether the fee iswas fixed and determinable based on the payment terms associated with the transaction. If a fee is based upon a variable such as acceptance by the customer, the Company accounts for the fee as not being fixed and determinable. In these cases, the Company defers revenue and recognizes it when it becomes due and payable. The Company assesses the probability of collection based on a number of factors, including past transaction history with the customer and the current financial condition of the customer. If the Company determines that collection of a fee is not reasonably assured, revenue is deferred until the time collection becomes reasonably assured.

~~The~~If a fee was based upon a variable such as acceptance by the customer, the Company ~~anticipates~~accounted for the fee as not being fixed and determinable. In these cases, the Company defers revenue ~~from~~and ~~support~~recognizes ~~agreements~~it when it ~~enters~~becomes ~~into~~due ~~will~~and bepayable. ~~recognized~~The Company assessed the probability of collection based on a ~~straight-line~~number ~~basis~~of ~~over~~factors, including past transaction history with the ~~life~~customer and the current financial condition of the ~~contract,~~customer. ~~although~~If the ~~fee~~Company isdetermined ~~due~~that ~~and~~collection ~~payable~~of ata ~~the~~fee ~~time~~was ~~the~~not ~~agreement~~reasonably isassured, ~~signed~~revenue orwas ~~upon~~deferred ~~annual~~until ~~renewal.~~the time collection became reasonably assured.

Accounts Receivable

The Company intends to conduct business with companies based on an evaluation of each customer’s financial condition, generally without requiring collateral. Exposure to losses on receivables is expected to vary from customer to customer due to the financial condition of each customer. The Company monitors exposure to credit losses and maintains allowances for anticipated losses considered necessary under the circumstances. Management has determined that there is anno allowance ~~of $72,115~~ for doubtful accounts at ~~March~~June 3130, 2012.

Accounts receivable will generally be due within 30 days and collateral is not required.

Income Taxes

Under ASC 740 the liability method is used in accounting for income taxes. Under this method, deferred tax assets and liabilities are determined based on differences between financial reporting and tax bases of assets and liabilities, and are measured using the enacted tax rates and laws that will be in effect when the differences are expected to reverse.

Uncertainty in Income Taxes

Under ASC 740-10-25 recognition and measurement of uncertain income tax positions is required using a “more-likely-than-not" approach. Management evaluates their tax positions on an annual basis and has determined that as of ~~March~~June 3130, 2012 no additional accrual for income taxes is necessary.

Fixed Assets

Fixed assets are stated at cost. Depreciation is computed using the straight-line method over the estimated useful lives of the assets.

When assets are retired or otherwise disposed of, the costs and related accumulated depreciation are removed from the accounts, and any resulting gain or loss is recognized in income for the period. The cost of maintenance and repairs is charged to income as incurred; significant renewals and betterments are capitalized. Deduction is made for retirements resulting from renewals or betterments.

Impairment of Long-Lived Assets

Long-lived assets, primarily its licenses and fixed assets, are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of the assets might not be recoverable. The Company does not perform a periodic assessment of assets for impairment in the absence of such information or indicators. Conditions that would necessitate an impairment assessment include a significant decline in the observable market value of an asset, a significant change in the extent or manner in which an asset is used, or a significant adverse change that would indicate that the carrying amount of an asset or group of assets is not recoverable. For long-lived assets to be held and used, the Company recognizes an impairment loss only if its carrying amount is not recoverable through its undiscounted cash flows and measures the impairment loss based on the difference between the carrying amount and estimated fair value.

(Loss) Per Share of Common Stock

Basic net (loss) per common share is computed using the weighted average number of common shares outstanding. Diluted earnings per share ("EPS") include additional dilution from common stock equivalents, such as stock issuable pursuant to the exercise of stock options and warrants. Common stock equivalents were not included in the computation of diluted earnings per share on the consolidated statement of operations due to the fact that the Company reported a net loss and to do so would be anti-dilutive for the periods presented.

The following is a reconciliation of the computation for basic and diluted EPS:

~~March~~June 3130, 2012

~~March~~June 3130, 2011

Net loss

$ (2411,~~192,193~~717)

$ (~~299~~573,~~524~~670)

Weighted-average common shares

Outstanding (Basic)

7,~~805~~846,~~886~~957

5,~~365~~832,~~706~~592

Weighted-average common stock

Equivalents

Series A1 Preferred Stock

2,000,000

Series D Preferred Stock

3,440,000

Series E Preferred Stock

895,291

Warrants

2,685,873

Stock options

1,122,498

Convertible Notes into Series D

51 6,~~720~~923

Convertible Notes into common

~~510~~ 2,~~519~~266,547

54,~~507~~587,~~246~~500

Weighted-average commons shares

Outstanding (Diluted)

1820,~~511~~264,~~787~~089

13,~~995~~542,~~450~~590

In addition, the Company has issued the placement agent a Series E Preferred Stock Warrant.

Stock-Based Compensation

In 2006, the Company adopted the provisions of ASC 718-10 “Share Based Payments". The adoption of this principle had no effect on the Company’s operations.

ASC 718-10 requires recognition of stock-based compensation expense for all share-based payments based on fair value. Prior to January 1, 2006, the Company measured compensation expense for all of its share-based compensation using the intrinsic value method.

The Company has elected to use the modified-prospective approach method. Under that transition method, the calculated expense in 2006 is equivalent to compensation expense for all awards granted prior to, but not yet vested as of January 1, 2006, based on the grant-date fair values. Stock-based compensation expense for all awards granted after January 1, 2006 is based on the grant-date fair values. The Company recognizes these compensation costs, net of an estimated forfeiture rate, on a pro rata basis over the requisite service period of each vesting tranche of each award. The Company considers voluntary termination behavior as well as trends of actual option forfeitures when estimating the forfeiture rate.

The Company measures compensation expense for its non-employee stock-based compensation under ASC 505-50, “Accounting for Equity Instruments that are Issued to Other Than Employees for Acquiring, or in Conjunction with Selling, Goods or Services". The fair value of the option issued is used to measure the transaction, as this is more reliable than the fair value of the services received. The fair value is measured at the value of the Company’s common stock on the date that the commitment for performance by the counterparty has been reached or the counterparty’s performance is complete. The fair value of the equity instrument is charged directly to compensation expense and additional paid-in capital. For common stock issuances to non-employees that are fully vested and are for future periods, the Company classifies these issuances as prepaid expenses and expenses the prepaid expenses over the service period. At no time has the Company issued common stock for a period that exceeds one year.

Segment Information

The Company follows the provisions of ASC 280-10, "Disclosures about Segments of an Enterprise and Related Information". This standard requires that companies disclose operating segments based on the manner in which management disaggregates the Company in making internal operating decisions. The Company operates in ~~five~~four distinct reporting segments, as of ~~March~~June 3130, 2012 and for the ~~three~~six months ended ~~March~~June 3130, 2012 and four distinct reporting segments as of June 30, 2011 and for the six months ended June 30, 2011.

Inventory

Inventory iswas valued at the lower of cost (on a first-in, first-out (FIFO) basis) or market. ~~Inventory~~All ofremaining ~~$190,905~~inventory as of March 31, 2012 ~~consists~~of $190,905 which consisted of donor’s sperm samples. ~~Based~~were onsold ~~the method~~ in ~~which~~the ~~these~~disposition samples are contained, it is very rare that a sample would spoil. Samples are cleared for cryopreservation after rigorous laboratory testing. Samples are cryopreserved in nitrogen vapor and are maintained frozen until purchased by a client. There has been no reserve for obsolescence of ~~inventory and inventory is only removed upon use.~~ The ~~Company,~~Sperm toBank ~~date~~of ~~has~~New ~~never destroyed any samples in inventory~~York, ~~or sold samples that were not viable (alive after been thawed for use)~~Inc.

Beneficial Conversion Features

ASC 470-20 applies to convertible securities with beneficial conversion features that must be settled in stock and to those that give the issuer a choice in settling the obligation in either stock or cash. ASC 470-20 requires that the beneficial conversion feature should be valued at the commitment date as the difference between the conversion price and the fair market value of the common stock into which the security is convertible, multiplied by the number of shares into which the security is convertible. ASC 470-20 further limits this amount to the proceeds allocated to the convertible instrument.

Recent Accounting Pronouncements

In May 2011, FASB issued Accounting Standards Update (ASU) No. 2011-04, Amendments to Achieve Common Fair Value Measurement and Disclosure Requirements in U.S. GAAP and IFRSs. FASB ASU 2011-04 amends and clarifies the measurement and disclosure requirements of FASB ASC 820 resulting in common requirements for measuring fair value and for disclosing information about fair value measurements, clarification of how to apply existing fair value measurement and disclosure requirements, and changes to certain principles and requirements for measuring fair value and disclosing information about fair value measurements. The new requirements are effective for fiscal years beginning after December 15, 2011. The Company plans to adopt this amended guidance on October 1, 2012 and at this time does not anticipate that it will have a material impact on the Company’s results of operations, cash flows or financial position.

In June 2011, FASB issued ASU No. 2011-05, Presentation of Comprehensive Income, which amends the disclosure and presentation requirements of Comprehensive Income. Specifically, FASB ASU No. 2011-05 requires that all nonowner changes in stockholders’ equity be presented either in 1) a single continuous statement of comprehensive income or 2) two separate but consecutive statements, in which the first statement presents total net income and its components, and the second statement presents total other comprehensive income and its components. These new presentation requirements, as currently set forth, are effective for the Company beginning October 1, 2012, with early adoption permitted. The Company plans to adopt this amended guidance on October 1, 2012 and at this time does not anticipate that it will have a material impact on the Company’s results of operations, cash flows or financial position.

In September 2011, FASB issued ASU 2011-08, Testing Goodwill for Impairment, which amended goodwill impairment guidance to provide an option for entities to first assess qualitative factors to determine whether the existence of events or circumstances leads to a determination that it is more likely than not that the fair value of a reporting unit is less than its carrying amount. After assessing the totality of events and circumstances, if an entity determines that it is not more likely than not that the fair value of a reporting unit is less than its carrying amount, performance of the two-step impairment test is no longer required. This guidance is effective for annual and interim goodwill impairment tests performed for fiscal years beginning after December 15, 2011, with early adoption permitted. Adoption of this guidance is not expected to have any impact on the Company’s results of operations, cash flows or financial position.

There were other updates recently issued, most of which represented technical corrections to the accounting literature or application to specific industries and are not expected to have a material impact on the Company’s financial statements upon adoption.

NOTE 3 -FIXED ASSETS

Fixed assets as of ~~March~~June 3130, 2012 (unaudited) and December 31, 2011 were as follows:

Estimated

Useful Lives ~~March~~June 3130, December 31,

(Years) 2012 2011

Computer Equipment

$ 25,916

$ 13,281

Machinery and Equipment

5-7

5,868 5,868

Leasehold Improvement

20,980 20,980

Furniture and fixtures

28,350 28,350

6881,~~479~~114 68,479

Less: accumulated depreciation

(4749,~~706~~229) (45,700)

Fixed assets, net

$ 2031,~~773~~885 $ 22,779

There was $23,~~006~~529 and $24,~~287~~575 charged to operations for depreciation expense for the ~~three~~six months ended ~~March~~June 3130, 2012 and 2011, respectively.

NOTE 4 - INTANGIBLE ASSETS AND INTELLECTUAL PROPERTY LICENSE

Intangible assets as of ~~March~~June 3130, 2012 (unaudited) and December 31, 2011 were as follows:

Estimated

Useful Lives ~~March~~June 3130, December 31,

(Years) 2012 2011

Patents and Trademarks

$~~315~~337,~~878~~730

$301,161

Less: accumulated amortization

( 5563,~~640~~537) (48,111)

Intangible assets, net

$ ~~260~~274,~~238~~193 $ 253,050

~~The Intellectual Property License as of March 31, 2012 (unaudited) and December 31, 2011 were as follows:~~ 12

The Intellectual Property License as of June 30, 2012 (unaudited) and December 31, 2011 were as follows:

Estimated

Useful Lives ~~March~~June 3130, December 31,

(Years) 2012 2011

Intellectual Property License

$3,401,894

$3,401,891

Less: accumulated amortization

(~~652~~737,~~029~~076) (566,982)

Intellectual Property License, net $ 2,~~749~~664,~~862~~818 $ 2,834,909

There was $92185,~~576~~520 and $91184,~~618~~709 charged to operations for amortization expense for the ~~three~~six months ended ~~March~~June 3130, 2012 and 2011, respectively.

NOTE 5 - RELATED PARTY LOANS

The Company has unsecured loans and advances from officers of $~~692~~599,~~931~~154 as of ~~March~~June 3130, 2012. The loans and advances are ~~typically~~considered ~~repaid through conversions to shares of common stock. The advances are~~ short-term ~~and typically repaid within 6 months~~. The officers have not accrued interest on these amounts through December 31, 2010 as the repayment of the advances were made on a recurring basis. Effective, January 1, 2011, the board of directors agreed to pay 3% interest on all amounts outstanding. Interest expense for the ~~three~~six months ended ~~March~~June 3130, 2012 and 2011 on these loans are $510,~~409~~137 and $510,~~317~~894, respectively, and accrued for as of ~~March~~June 3130, 2012 on these loans amounts to $3033,~~306~~311. These loans were made to fund the Company with working capital during the process of securing contracts. All loans and advances are due on demand and are included in current liabilities. In addition, the Company has other related party payables outstanding that consist of accrued compensation and related expenses to the President and ~~former~~other ~~CFO~~senior management of the Company totaling $1,~~701~~732,~~667~~500 as of ~~March~~June 3130, 2012. This amount has been included in current liabilities on the consolidated balance sheets. In January 2011, the Company issued previously approved shares of the Company common stock to Michael Cohen, 625,000 shares for debt conversion of $350,000, and Steven Byle, 178,572 shares for debt conversion of $100,000.

NOTE 6 – CONVERTIBLE NOTES

The Company entered into an agreement with a company that was owed shares of stock and this was recorded as a liability for stock to be issued. This Company as of December 17, 2010 was owed 1,208,500 shares of common stock valued at $2,000,000. The shares were accrued at various dates from 2009 and 2010. The Company agreed to convert their liability of stock to be issued to them to a convertible note. The note is convertible at the holders request at the market value of the stock at the time of the request for conversion, or may be paid in cash at the time of a financing.

The Board of Directors agreed to charge a 3% interest rate on this note effective January 1, 2011. On December 31, 2010, the Company converted $100,000 into 200,000 shares of stock ($0.50), which was the fair value of the stock on the date of the conversion. There were conversions of $591,500 into 1,500,000 shares of common stock in the year ended December 31, 2011. In addition, this company issued there shares equivalent to $90,000 to a third party for services during the year ended December 31, 2011, and the Company added the $90,000 to the note balance. ~~As of March 31, 2012 the balance on the convertible note is $1,480,506.~~ During the ~~three~~six months ended ~~March~~June 3130, 2012, this company paid $82,006 in expenses on behalf of the Company, and this amount has been added to the note balance. During the six months ended the Company repaid $7,250 of this note. As of June 30, 2012 the balance on the convertible note is $1,473,256. The Company has reflected this note as a current liability as it is due on demand. The interest expense for the ~~three~~six months ended ~~March~~June 3130, 2012 and 2011 are $1021,~~792~~852 and $1427,~~055~~961, respectively and accrued for on the note as of ~~March~~June 3130, 2012 is $6273,~~309~~369.

On December 23, 2011, the Company entered into a convertible promissory note with an individual in the amount of $150,000. The convertible promissory note bears interest at 8% per annum and matures on December 23, 2016. This individual shall have the right to convert all or part of the principal and interest into the Class D Preferred Stock of the Company during the time period commencing December 23, 2011 and ending upon the repayment of the convertible promissory note. This convertible promissory note shall be convertible at a price equal to ten times the average price of the Company’s common stock in the open market based upon the average of the closing bid prices for the common stock for the twenty trading days prior to receipt by the Company of the Election of Conversion less 12% percent. In April 2012, $105,000 of this note was repaid leaving a balance of $45,000 at June 30, 2012. The interest expense for the ~~three~~six months ended ~~March~~June 3130, 2012 and 2011 is $24,~~992~~097 and $0, respectively and accrued as of ~~March~~June 3130, 2012 is $34,~~222~~327.

NOTE 7 - LICENSING AGREEMENTS

The John Hopkins University

OnIn ~~November~~March 142006, ~~2005,~~ the Company subsidiary, National Stem Cell, Inc. (NSC) entered into an intellectual property licensing agreement with The John Hopkins University (“JHU"). The license agreement relates to certain patents pending and contains royalty payment arrangements as well as funding guarantees.

Due to certain internal JHU intellectual property timeline issues regarding technology development with NSC and the NSC’s failure to pay fees in connection with the development, JHU discontinued the Company’s research plan and terminated the agreement.

During 2005 and 2006, $296,250 was recognized as license fees and remained outstanding as of December 31, 2007. During 2008, the Company and JHU negotiated a settlement agreement which was executed on September 24, 2008. The settlement agreement stipulated that should a $10,000 payment be made, the total amount due would be reduced to $190,000. The Company made the payment and the Company recognized $96,250 in forgiveness of the JHU payable. As of September 30, 2010, NSC has $190,000 outstanding, respectively to JHU under the terms of the agreement.

16During the third and fourth quarters of 2010, NSC made payments totaling $100,000 towards this obligation. The Company and JHU agreed on a settlement and during June 2012, the Company paid $85,000 to JHU to settle all outstanding amounts due to JHU.

During the third and fourth quarters of 2010, NSC made payments totaling $100,000 towards this obligation. As of March 31, 2012, the total outstanding liability is $90,000. However, NSC is currently in default on the John Hopkins obligation and on June 17, 2011 JHU obtained judgment by consent and JHU has not yet commenced collection activity. NSC plans to continue paying this obligation if and when funded.

The Stromal Cell Technology License

On ~~May~~June 418, ~~2010~~2012, ~~Proteonomix licensed from~~ the ~~Cohen-McNiece~~Company ~~Foundation~~entered ~~the~~into ~~Stromal~~an ~~Cell~~Exclusive ~~technology~~License ~~for~~Agreement ~~potential~~with ~~therapeutic~~Ian ~~use in the regrowth of damaged cardiac cells after a heart attack. The Cohen-~~McNiece ~~Foundation was formed by Proteonomix President~~, ~~Michael~~the ~~Cohen,~~Company’s ~~and its~~ Chief Scientific Officer ~~and~~(the ~~Vice-President,~~“Licensor”). ~~Ian~~Under ~~McNiece,~~the ~~PhD~~terms toof ~~develop~~the ~~cellular~~Exclusive ~~technology~~License ~~for~~Agreement, ~~patients~~the ~~who~~Licensor ~~have~~hereby ~~suffered~~grants ~~myocardial~~to ~~infarctions. The~~the ~~Technology~~Company ~~was~~an ~~licensed~~exclusive, inworldwide, ~~exchange~~royalty ~~for~~bearing alicense, 2%with ~~royalty~~the onright ~~gross~~to ~~revenue~~grant ~~derived~~sublicenses ~~from~~to ~~use of~~ the ~~StromalCel~~ Technology ~~and 1~~,~~000,000~~ ~~stock~~Licensed ~~options exercisable for five years at $3.55 per share vested immediately to Michael Cohen~~Products, ~~our~~Licensed ~~President~~Improvements and ~~90%~~Patents ~~owner~~as ofnoted in the ~~Cohen-McNiece Foundation~~agreement.

The 2%Company ~~royalty~~ will bepay ~~used~~the byLicensor the ~~Foundation~~amounts toset doforth ~~further~~herein ~~research~~upon ~~into~~the ~~stem~~first ~~cell~~occurrence ~~applications.~~of ~~Proteonomix~~each ~~also~~of ~~received~~the afollowing ~~right~~milestone events: (1) License fee (upon execution of ~~first~~the ~~refusal~~agreement) to- ~~license~~$100,000; ~~any~~(2) Agreement with a third party related to this technology ~~developed~~- $250,000 and 50,000 shares of common stock; (3) Successful patent issue - $50,000; (4) Isolation of the active factor for tumor inhibition - $50,000; (5) Initiation of the Phase I clinical trial of the Licensed Products - $100,000; and (6) Grant by or marketing approval of the ~~Foundation~~Licensed Product in the US (FDA) or Europe - $500,000. The license fee of $100,000 was paid in June 2012.

~~Proteonomix~~Upon ~~has~~the ~~sub-licensed~~First Commercial Sale of Licensed Product, the ~~StromaCel~~Company ~~Technology~~shall pay to ~~StromaCel~~the ~~for~~Licensor a 2% royalty, ~~but~~of ~~Proteonomix~~three ~~will~~percent ~~remain~~(3%) ~~responsible~~of ~~for~~Net ~~all~~Sales ~~costs~~of ~~associated~~a ~~with~~Licensed ~~patent~~Product ~~prosecution~~during ~~for~~ the ~~StromaCel~~Royalty ~~Technology~~Term, as described therein. In addition, the ~~event~~Company ofshall ~~bankruptcy,~~pay ~~the~~to ~~rights~~Licensor an amount equal to ~~the~~three ~~Technology~~percent ~~granted~~(3%) byof the ~~license~~Sublicense ~~revert~~Fee toreceived ~~the~~from ~~Foundation~~any Sublicense.

The Company has determined that the estimated useful life of the Intellectual Property License is ten years, and the Company commencing May 2010 began to amortize the license over this ten-year period. In addition, the Company performed its annual impairment test on the value of this license and determined that no further impairment is necessary at March 31, 2012.

On February 1, 2011 the Company announced that it has filed an additional patent on the StromaCel technology that was intended to improve the Company's patent position on StromaCel with respect to a newly developed breakthrough method of stem cell expansion.

NOTE 8 - COMMITMENTS

Lease Agreement

The Company in 2012 commenced sub leasing office space in the offices of their attorneys. The Company utilizes a few offices on a month to month basis. The Company has paid $2,500 for the six months ended June 30, 2012.

Employment Agreements with Officers

The Company has entered into an employment agreement with its President and CEO. The agreement obligates the Company to pay this officer base compensation of $325,000 per year which includes a $75,000 bonus. The Company and the officer can terminate this agreement, and can adjust compensation at anytime during the length of the contract. In addition, the officer is to receive 50,000 shares of common stock for each patent filed in which he is named as inventor or investigator. The Company has issued all shares under this agreement. On July 1, 2009, the Company and its President and CEO, modified the employment agreement to include: a) the Company’s recognition of the assignment by the President and CEO at no additional consideration by the Company of the technologies, including the patent applications to the Company’s subsidiary, National Stem Cell, Inc.; b) for the transfer of the 2 Proteoderm patents and future patent applications related to inventions and discoveries related to stem cell derived cosmetics and cosmeceuticals, 50,000 Series C Preferred Shares with a par value of $0.001 (see Note 10) and the right to receive 20% of the outstanding shares of the Company’s subsidiary, Proteoderm, Inc. in the event it shall become a public company.

The right set forth above shall be non-transferable except to the JSM Family Trust (of which 25,000 of these shares were transferred to the JSM Family Trust on July 10, 2011); and c) an increase in the vehicle allowance to $1,000 per month.

On March 2, 2012, the Company entered into an employment agreement with Steven Byle to act as the Company’s Chief Technology Officer. Pursuant to the employment agreement, the Company has agreed to pay Mr. Byle an initial salary of$150,000 per annum (the “Base Fee”) in bi-weekly installments. Mr. Byle was entitled to an increase to $200,000 per annum at such time as the Company has received $3,000,000 in financing in March 2012 and will be raised to $250,000 per year when the Company has raised $5,000,000 in financing and increased to $300,000 per year when the Company’s common stock is traded on a listed exchange. Mr. Byle also received a signing bonus of 100,000 shares of Series D Preferred Stock.

On March 2, 2012, the Company has entered into an agreement with Roger Fidler to provide legal services for a salary of $120,000 per annum when the Company has received $3,000,000 in financing in March 2012 and will be increased to $240,000 per year when the Company has obtained $5,000,000 in financing. Mr. Fidler also received a signing bonus of 35,000 shares of Series D Preferred Stock. He also received payment of 35,000 shares of Series D Preferred Stock for services rendered during 2011.

On July 1, 2009, the Company entered into an employment agreement with Robert Kohn, pursuant to which Mr. Kohn serves as Chief Financial Officer until June 29, 2012. Pursuant to the agreement, Mr. Kohn is entitled to receive a salary of $150,000 per annum which accrues until the Company receives $1,500,000 in equity, debt or joint venture funding. Mr. Kohn will receive an additional $50,000 per annum if the Company receives $3,000,000 in debt, equity or joint venture funding and an additional $50,000 per annum if the Company receives $10,000,000 in debt, equity or joint venture funding. In addition, Mr. Kohn is entitled to the issuance of 250,000 shares of common stock upon the execution of the employment agreement as a signing bonus.

Mr. Kohn also receives an additional 250,000 shares upon the spin-off of any subsidiary as a public company in the event such spin-off occurs during the term of the agreement.

In addition, Mr. Kohn receives a benefits package including health insurance, vision, dental, and life insurance. In addition, pursuant to his employment agreement, Mr. Kohn is entitled to reimbursement for all medical and dental expenses for himself and his immediate family which are not covered by insurance. The agreement is for a term of three years from July 1, 2009, unless terminated by the Company or Mr. Kohn by written notice given 90 days prior to the expiration of the agreement. The agreement may also be terminated by us for "cause," as such term is defined in the agreement. Upon termination, Mr. Kohn will only be entitled to accrued salary, and benefits which have vested at the time of termination. On September 30, 2010, the Company and Mr. Kohn entered into a Separation Agreement, and in accordance with the terms of the agreement, Mr. Kohn will relinquish his duties as CFO and in return, receive $187,500 of his accrued compensation, $37,500 of his accrued fringe benefits, and keep 156,250 shares of common stock he received for his signing bonus, and return the 93,750 shares that were received in October 2010.

Consulting Agreements

The Company has entered into consulting agreements with consultants to assist in developing the Company’s business. The agreements range in term from one year to three years. The agreements call for the issuance of common stock as the Company does not have sufficient cash flow to compensate its consultants with cash.

InDuring ~~December 2009,~~ the ~~Company~~six ~~entered~~months ~~into~~ended aJune ~~three year agreement with the Company’s Chief Scientific Officer and Vice-President~~30, ~~Ian McNiece~~2012, ~~PhD. Under~~ the ~~terms of the agreement Mr. McNiece will receive $4,000 per month for three years which is accrued until the~~ Company ~~has~~settled ~~received~~all ~~$3,000,000~~amounts indue ~~equity~~to ~~or convertible debt financing. Furthermore~~Wolfe, ~~Mr.~~Axelrod ~~McNiece will receive 200,000 shares of common stock- 50,000 shares on the first~~ and ~~second~~Weinberger ~~anniversary of the signing of the agreement~~ and ~~100,000~~no ~~shares~~balance atremains ~~the~~open ~~end of the agreement. The Company accrued the first 50,000 shares~~ as of ~~December~~June ~~31, 2010, and the second 50,000 shares on December 31, 2011. On December 31, 2011, the Company amended this agreement and will replace the accrued 100,000 shares of common stock with~~ 30,~~000~~ ~~shares of the Company’s Series D Preferred Stock~~2012. The ~~consultant~~Company has ~~agreed~~expensed ~~to continue accruing the amounts through the end of the agreement~~ in ~~December~~stock-based ~~2012.~~compensation ~~At that time~~37,500 ~~the~~options ~~Company~~at ~~will~~a ~~either~~value ~~convert this into shares~~ of ~~common stock or pay cash for the amount accrued~~$72,507.

Effective June 1, 2010, the Company entered into a one year agreement at $7,500 per month with Wolfe, Axelrod and Weinberger to provide marketing services. Wolfe, Axelrod and Weinberger will receive 75,000 stock options @$5.00 per share ratably over twelve months commencing July 1, 2010. The Company has a right to terminate the agreement after three months including all fees and stock options. The maximum stock options to be issued, if terminated, would be 18,750 shares. The Company has expensed $30,000 through December 31, 2010, and issued 10,000 shares of stock in October 2010 to cover 2 additional months of service through November 30, 2010. The Company has not utilized the services subsequent to November 30, 2010 and terminated this agreement at that time.

There is currently $15,000 due to Wolfe, Axelrod and Weinberger as of March 31, 2012. The Company has expensed in stock-based compensation 37,500 options at a value of $72,507.

On June 15, 2010 the Company entered into a three month agreement with Logoform AG to perform business development, research and related investment relations services. Logoform AG received 100,000 stock options @ $5.00 per share exercisable until June 15, 2011, ratably over twelve months commencing July 15, 2010. The Company has expensed 49,998 options through December 31, 2010 as stock-based compensation in accordance with the terms of the agreement. There will be no additional options granted subsequent to December 31, 2010 as the contract has been terminated. The value of the options was $96,673 for the year ended December 31, 2010 relating to these options.

On September 20, 2010 the Company entered into an agreement for investor relation services with a consultant. The agreement has a one-year term. As compensation under the agreement, the Company issued 100,000 shares of common stock valued at $50,000, the fair value of the common stock at the time of issuance. The Company terminated this agreement on or about April 1, 2011. The Company is currently negotiating with the investor relation consultant on the return of shares due to the termination of this agreement.

The Company entered into a Consulting Agreement in November, 2011 pursuant to which the Company issued 100,000 shares of its restricted common stock for providing services for management consulting, business advisory, shareholder information and public relations. The Consultant also received 100,000 shares of common stock from a third party for which the Company will incur an obligation to the third party in the amount of $100,000.

In October 2011, the Company engaged a consultant to assist the Company in development of new business opportunities, develop proposals and term sheets for such prospects and the drafting of legal documents. The term of the agreement is for a period of three years and compensation will be in the form of the Company’s Series D Preferred Stock. The Consultant was entitled as part of the consulting contract to receive 30,000 Series D Preferred shares with 10,000 shares vesting immediately, and an additional 10,000 Series D Preferred shares vesting on each of the first and second anniversary dates of the consulting agreement. The initial 10,000 shares of the Series D Preferred Stock were issued January 3, 2012.

License Agreement

In January 2009, the Company entered into a three-year license and purchase agreement with two China based companies for the exclusive license of the Proteoderm products in China, Hong Kong and Taiwan (the “territory"). The agreement includes pricing, delivery and minimum purchase requirements for the China-based companies of these products. Through ~~March~~June 3130, 2012, no products have been purchased. The Company did not meet the terms of the agreement due to delays in financing. This agreement had expired in January 2012 and has not been extended.

Litigation

The Company has been threatened to be sued by Fred Grant, a consultant who introduced the Company to Ice Cold Stocks.com. The Company denies the claim. ~~The Company has recently been sued by Wolf Axelrad for $38,000. The Company intends to vigorously defend this action.~~

James Magee, President of GEM Media, who contends the Company has responsibility for $350,000 of charges associated with the failed XGen Dubai project and Mark Huggins of Hulk Media who alleges liability for $60,000 in commissions for the introduction to GEM and other related consulting services. The Company believes it has meritorious defenses to both of these assertions and would defend any litigation that arises from these allegations vigorously.

On March 22, 2011, the Company was notified by a collection agency regarding a debt owed to a prior law firm in the amount of $168,812. The Company has negotiated a settlement with the prior law firm, and in March 2012 paid $125,000 to settle this claim.

The former CFO of the Company, Robert Kohn, has threatened litigation regarding an amount due under a Separation Agreement in the amount of $156,000. The Company believes that it has meritorious defenses to the claim and intends to vigorously contest any lawsuit concerning this matter.

OnA ~~April~~former ~~24,~~law ~~2012,~~firm that has entered bankruptcy claims that the Company ~~was~~owes ~~served~~it ~~with~~approximately a$200,000. The ~~subpoena~~Company ~~from~~in the ~~United~~six ~~States~~months ~~Securities~~ended ~~and~~June ~~Exchnage~~30, ~~Commission~~2012 ~~pursuant~~settled tothe aoutstanding ~~formal~~debt ~~investigation~~in ~~“In~~ the ~~Matter~~amount of ~~Proteonomix~~$100,000, ~~Inc.~~with ~~HO-11836”~~the remaining amounts forgiven.

A former law firm that has entered bankruptcy claims that the Company owes it approximately $200,000. The Company is presently negotiating with the Trustee regarding payment of the debt.

NOTE 9 -STOCKHOLDERS’ EQUITY (DEFICIT)

Preferred Stock

InAs ~~April~~of ~~2009~~June 30, 2012, the Company ~~had~~has ~~determined~~10,000,000 ~~that~~shares itof ~~had~~preferred ~~not~~stock ~~obtained~~authorized with a par value of $.001. The Company increased the ~~proper~~authorized ~~authorization~~shares ~~required~~from 4,000,000 to ~~issue~~10,000,000 ~~any~~on ~~classes~~July of21, ~~its~~2008. The preferred stock~~. As~~ amay ~~result,~~be itissued ~~was~~from ~~determined~~time ~~that~~to ~~the~~time, ~~issuance~~in ofone ~~the~~or ~~Company’s~~more ~~Class~~series, Aeach ~~and~~series ~~Class~~to Bbe ~~Preferred~~appropriately ~~Stock~~designated ~~were~~by ~~never~~a ~~legally~~distinguishing ~~executed,~~letter asor ~~such~~title, doprior ~~not~~to ~~exist. Therefore,~~the asissue of ~~January,~~any ~~2005~~shares thereof. In August 2008, the Company’s ~~established~~board anof ~~unsettled~~directors ~~obligation~~approved toa ~~the~~1:10 ~~holders~~reverse ofsplit. ~~any~~All ~~aforementioned~~shares ~~Class~~reflected Ain ~~and~~the ~~Class~~condensed Bconsolidated ~~Preferred~~financial ~~Stock~~statements are shown post-split.

As of March 31, 2012, the Company has 10,000,000 shares of preferred stock authorized with a par value of $.001. The Company increased the authorized shares from 4,000,000 to 10,000,000 on July 21, 2008. The preferred stock may be issued from time to time, in one or more series, each series to be appropriately designated by a distinguishing letter or title, prior to the issue of any shares thereof. In August 2008, the Company’s board of directors approved a 1:10 reverse split. All shares reflected in the condensed consolidated financial statements are shown post-split.

In May 2009, the Company formally designated three series of preferred stock; the Series A Convertible Preferred Stock consists of 200,000 shares, convertible into common stock, each share for 10 shares of common stock; the Series B Preferred Stock which consists of 6 shares; and the Series C Preferred Stock which consists of 50,000 shares. In November 2011, the Company amended its designation of the Series A Preferred Stock and Series C Preferred Stock to provide anti-dilution protection against both forward and reverse splits of the Company’s common stock and other reorganizations of similar nature. In the event that the common stock of the Company is subject to a reverse split, the number of shares into which the Series A and the Series C Preferred Stock are convertible remain unchanged. The Series C was amended to provide convertibility into the common stock of the Company at the option of the holder at a ratio of 10 common shares for each share of Series C Preferred Stock.

On December 29, 2011, the Company amended its designation in Delaware of the Series A Preferred Stock and Series C Preferred Stock to provide anti-dilution protection against both forward and reverse splits of the Company’s common stock and other reorganizations of similar nature. In the event that the common stock of the Company is subject to a reverse split, the number of shares into which the Series A and the Series C Preferred Stock are convertible remain unchanged. The Series C was amended to provide convertibility into the common stock of the Company at the option of the holder at a ratio of 100 common shares for each share of Series C Preferred Stock.

On December 29, 2011, a new Series D Preferred Stock was designated in Delaware authorizing the issuance of 2,000,000 shares of the Series D Preferred Stock that is convertible into the common stock of the Company at a ratio of ten shares of common for each share of Series D Preferred Stock that is converted. The Series D Preferred Stock is also protected against dilution in the event of forward splits, reverse splits and reorganizations. In the event of a reverse split, the number of shares issued upon conversion of the Series D Preferred Stock remains unchanged.

In January 2012, Series D shares were issued to Michael Cohen in the amount of 130,000 shares in lieu of $100,000 of debt forgiveness, Steven Byle in the amount of 100,000 shares for services rendered, Ian McNiece in the amount of 30,000 shares as an amendment to his 2009 Consulting Agreement obviating the need for the Company to issue to him 100,000 shares of common stock, and Roger Fidler in the amount of 70,000 shares for legal services rendered and his agreement to provide legal services to the Company in the future. In addition, 14,000 other Series D Preferred shares have been approved for issuance in 2011. All expenses related to these shares have been accrued in 2011. The Company has also approved for issuance an additional 20,000 shares that vest through December 31, 2013.

~~Each~~On ~~share~~March 5, 2012, the Company entered into a Securities Purchase Agreement (the “SPA”) with the purchasers identified therein (collectively, the “Purchasers”) providing for the issuance and sale by the Company to the Purchasers of an aggregate of approximately 3,804 shares of the Company’s newly designated Series AE Convertible Preferred Stock, iswith each of the Series E Convertible Preferred shares initially convertible into 10approximately 235 shares of the Company’s common stock. ~~The~~(the ~~Company~~“Conversion Shares”) and three series of warrants, ~~prior~~the toSeries ~~realizing~~A ~~that~~Warrants, the ~~preferred~~Series ~~stock~~B ~~had~~Warrants ~~not~~and ~~been~~the ~~properly~~Series ~~authorized~~C Warrants, ~~assumed~~to ~~that~~purchase itup ~~had~~to ~~issued~~an ~~200~~aggregate of 2,~~000~~685,873 shares of ~~Series~~the ACompany’s ~~Preferred~~common ~~Stock~~stock, infor ~~2005~~proceeds to ~~its~~the ~~President~~Company of $3.8 ~~The~~million. ~~200,000~~After ~~shares~~deducting ~~were~~fees ~~thought~~and toexpenses, ~~have~~the ~~been~~aggregate ~~issued~~net ~~for~~proceeds afrom ~~value~~the sale of athe Preferred Shares and associated warrants are approximately $23.5 million. Rodman & Renshaw,~~000~~ LLC (~~par~~“Rodman”) acted as ~~founders’~~the ~~shares~~exclusive placement agent for the private placement. AsPursuant ato ~~result,~~the terms of the ~~Company~~Placement ~~performed~~Agent anAgreement ~~informal~~entered ~~valuation~~into by the Company and ~~determined~~Rodman ~~there~~on ~~was~~February no15, ~~increase~~2012 in(the “Placement Agent Agreement”). In accordance with the ~~value~~Placement ofAgent Agreement, the ~~preferred~~placement ~~stock~~agent ~~and~~received as ofa ~~December 31~~fee, ~~2008,~~cash ~~there~~in ~~was~~the aamount of $2267,~~000~~249 ~~obligation~~and a Series E Preferred Stock Purchase Warrant, enabling the placement agent to ~~issue~~subscribe ~~preferred~~for ~~shares~~and onpurchase from the ~~consolidated~~Company ~~balance~~up ~~sheets~~to 266.3494 shares of Series E Preferred Stock, ~~respectively~~and 62,670 of each of the Series A, B and C Common Stock Warrants. ~~These~~This ~~shares~~Series ~~were~~E ~~issued~~Preferred Stock Purchase Warrant was valued at $1,293,509, and has been expensed in ~~May~~the ~~2009.~~six months ended June 30, 2012.

The Company also had assumed that it had properly issued 6 shares of Series B Preferred Stock. Each share of the Series B Preferred Stock enables the holder to nominate and appoint one member to the board of directors. The Company’s President was to be the holder of the six shares of Series B Preferred Stock, and upon proper authorization, the Company formally issued these shares to the President in May 2009. The Series B Preferred Shares value is par.16

On July 1, 2009, Michael Cohen and Jacob Cohen entered into a technology license agreement with Company relating to stem cell based cosmetic and cosmeceutical technologies they developed. The license agreement provides that they receive a) 50,000 Shares of the Company’s Series C Preferred Stock, par value $.001 per share and (b) the right to receive 20% of the outstanding shares of the Company’s subsidiary, Proteoderm, Inc. in the event it shall become a public company. The right set forth above shall be non-transferable except to the JSM Family Trust. Each share of Series C Preferred Stock shall be entitled to one hundred votes on all matters submitted to a vote of the Corporation’s shareholders. Jacob Cohen’s 25,000 shares were transferred on July 10, 2011 to the JSM Family Trust. The 50,000 shares of the Series C Preferred Stock were issued in July 2009.

Pursuant to the Certificate of Designation to create the Series E Convertible Preferred Stock, the Preferred Shares may be converted at any time at the option of the Purchasers into shares of the Company’s common stock at a conversion price of $4.25 per share (the “Conversion Price”). On each of (i) the Effective Date (as defined in the Registration Rights Agreement) or (ii) if the registration statement required to be filed by the Company pursuant to the Registration Rights Agreement is not declared effective on or before September 8, 2012 or if a Registration Statement does not register for resale by the Purchasers all of the Conversion Shares issuable hereunder, the date that all Conversion Shares issuable pursuant to the Preferred Shares may be resold by the Holder pursuant to Rule 144 without volume or manner restrictions (each such date, the “Trigger Date”), the Conversion Price shall be reduced to the lesser of (w) the then Conversion Price, as adjusted and taking into consideration any prior resets, (x) 85% of the volume average weighted price (“VWAP”) for the 5 trading days immediately following each such Trigger Date, as calculated pursuant to the AQR function on Bloomberg, L.P., (y) 85% of the average of the VWAP’s for each of the 5 trading days immediately following the Trigger Date, and (z) 85% of the closing bid price on the last trading day of the 5 trading days immediately following each such Trigger Date, which shall thereafter be the new Conversion Price. The adjusted Conversion Price shall not be lower than $1.00

Pursuant to the terms of the SPA, each Purchaser has been issued a Series A Warrant, a Series B Warrant and a Series C Warrant, each to purchase up to a number of shares of the Company’s Common Stock equal to 100% of the Conversion Shares underlying the Preferred Shares issued to such Purchaser pursuant to the SPA. The Series A Warrants have an exercise price of $4.25 per share, are exercisable immediately upon issuance and have a term of exercise equal to five years. The Series B Warrants have an exercise price of $4.25 per share, are exercisable immediately upon issuance and have a term of exercise of one year and two weeks. The Series C Warrants have an exercise price of $4.25 per share, vest and are exercisable ratably commencing on the exercise of the Series B Warrants held by each Purchaser (or its assigns) and have a term equal to five years.

On March 5, 2012, in connection with the closing of the private placement, the Company and the Purchasers entered into a Registration Rights Agreement (the “Registration Rights Agreement”). Under the Registration Rights Agreement, the Company is required to file a Registration Statement within 7 days following the filing date of the Company’s Form 10-K for the year ended December 31, 2011, but in no event later than April 16, 2012. The failure on the part of the Company to meet the filing deadlines and other requirements set forth in the Registration Rights Agreement may subject the Company to payment of certain monetary penalties.

~~March~~June 3130, 2012



Preferred Stock	Authorized Date	Issue Date	Number of Shares	Par Value	Conversion to Common Stock
Series “A" (1)	January 2005	May, 2009	200,000	$.001	10:1
Series “B" (1)	January 2005	May, 2009	6	$.001	None
Series “C" (2)	July 1, 2009	July 1, 2009	50,000	$.001	100:1
Series “D” (3)	December 29, 2011	Jan 2012	344,000	$.001	10:1
Series “E” (4)	March 5, 2012	March, 2012	3,804	$.001	235:1

(1) Issued to the President and CEO, Michael Cohen authorized in January 2005 as Founder’s shares.

(2) Issued equally to the President & CEO, Michael Cohen and his brother Jacob Cohen for the development of the Proteoderm products. Michael Cohen and Jacob Cohen (Jacob Cohen’s share has been since transferred to the JSM Family Trust) have the right to receive 20% of the outstanding shares of the Company’s subsidiary, Proteoderm, Inc. in the event it shall become a public company.

(3) In addition to these shares, the Company has authorized 20,000 shares to a consultant that vest through December 31, 2013. These shares have not been issued or accrued for.

(4) In addition, the Preferred E Stock carries with it three Classes of Warrants, each class of which can under certain circumstances convert into 895,291 shares of common stock.

Common Stock

AsIn ofthe ~~March~~six 31months ended June 30, 2012, the Company ~~has~~issued ~~240~~225,000~~,000~~ shares ofvalued ~~common~~at ~~stock~~$913,250 ~~authorized~~for ~~with~~services arendered ~~par~~and ~~value~~prepaid ofexpenses ~~$.001.~~as Onone ~~July~~of ~~21, 2008,~~ the ~~Company~~share ~~amended~~issuances ~~its~~is ~~certificate~~for ofservices ~~incorporation~~ to ~~increase~~be ~~the~~rendered ~~authorized~~through ~~shares~~January ~~from 50~~31,~~000,000~~ ~~to 240,000,000~~2013.

The Company has 7,885,556 shares issued and outstanding as of March 31, 2012.

The Company has had its common stock reverse split twice since 2006. In May 2006, the Company reverse split its shares 1:37 and then again in August 2008, the Company’s board of directors approved a 1:10 reverse split. All shares reflected in the condensed consolidated financial statements are shown post-split.

During 2007, the Company issued 124,987 shares of common stock for various services, marketing and interest valued at fair value at the time the services were performed. These services were valued at $685,676. In addition, the Company recorded a capital contribution of $30,000 from a third party with no shares of common stock being issued. The Company recorded this directly to additional paid in capital.

During 2008, the Company issued 224,106 shares of common stock for various services, marketing and interest valued at fair value at the time the services were performed or interest accrued. These services were valued at $1,320,414. In addition, the Company issued 582,200 shares of common stock (on April 14, 2008, approved for issuance on June 4, 2007) in conversion of loans from the Company’s President and accrued compensation to the Company’s President in the amount of $1,318,617. The value was determined based on average pricing at the times the liabilities were incurred.

In the year ended December 31, 2009, the Company issued 1,137,990 shares of common stock to consultants due for obligations arising from various marketing services and professional fees for services rendered from November 30, 2007 to November 18, 2008, for fair value at the time services were performed, valued at $5,082,780. The Board had authorized the shares to consultants at the time services were performed but the obligation was not satisfied until the share issuance in 2009.

During 2009, the Company authorized and issued 615,800 shares for various services including professional fees and marketing valued at $1,464,390 for the fair value at the time the services were performed. In addition, the Company issued 100,000 shares of common stock on November 18, 2009 in conversion of loans from the Company’s President for $150,000 and conversion of advances from our past Secretary of $75,000 in exchange for 50,000 shares of common stock. The shares were issued at fair value at the time of conversion.

In the year ended December 31, 2010 the Company issued 897,320 shares of common stock (net of 93,750 shares that were canceled) including 29,000 shares for professional fees for services rendered during the second quarter of 2010, for fair value at the time services were performed, valued at $73,950. The Board had authorized the shares to the professionals at the time services were performed. 250,000 shares were issued to Robert Kohn, our CFO, due November 1, 2009 under the terms of his employment contract. The Board had authorized the shares at November 1, 2009 but the obligation was not satisfied until the share issuance June 4, 2010 of these shares 93,750 shares ($66,563 value) were returned upon the execution of the Separation agreement as defined above. 354,070 shares were issued on April 15, 2010 to satisfy the outstanding promissory notes including settlement of all principal and interest. (See Note 5- Promissory Notes). 58,000 shares were issued to satisfy vendor payables ($58,767 value), 100,000 shares ($50,000 value) were issued in accordance with an investor relation agreement entered into in September and 200,000 shares ($100,000 value) were issued in conversion of a convertible note. In addition, the obligation for common stock to be issued at December 31, 2010 was reduced to $1,144,000, which represents 350,000 shares of common stock. During 2010, 953,500 shares were accrued for at a value of $1,739,625; $2,000,000 of this obligation was converted into a convertible note (1,208,500 shares); 414,125 shares ($300,594) were satisfied by stock issuances; and 31,750 shares ($27,563 value) that were previously accrued were written off during the year.

In the year ended December 31, 2011, the Company issued common stock to Michael Cohen, 625,000 shares for debt conversion of $350,000, and Steven Byle, 178,572 shares for debt conversion of $100,000. In addition, the Company issued 20,000 shares valued at $14,600 for services rendered. 1,500,000 shares of been issued in conversion of $591,500 in convertible notes payable; 150,000 shares have been issued to an investor relations company for services rendered for a period of twelve months for a total value of $48,000; and 50,000 shares issued to a consultant for services valued at $25,000. The shares issued are exempt from registration under Sec. 4(2) of the Securities Act of 1933.

In the three months ended March 31, 2012, the Company issued 200,000 shares valued at $899,500 for services rendered and prepaid expenses as one of the share issuances is for services to be rendered through January 31, 2013.

Warrants

~~The Company had no warrants outstanding as of March 4, 2012.~~ On March 5, 2012, the Company issued Class A Warrants, Class B Warrants and Class C Warrants in connection with the SPA. Additionally, the Placement Agent warrants were also issued upon the closing of the private placement.

March 31, 2012
June 30, 2012
Warrants	Number	Exercise Price	Term
Outstanding at Beginning of the Year	0
Series A Warrants	895,291	4.25	5 years
Series B Warrants	895,291	4.25	1 year 2 weeks
Series C Warrants	895,291	4.25	5 years
Warrants Outstanding at March 31, 2012	2,685,873
Warrants Outstanding at June 30, 2012	2,685,873

Options

The Board of Directors in 2010 approved the Proteonomix, Inc. 2010 Employees, Directors, Officers and Consultants Stock Option and Stock Award Plan (the “2010 Plan”). The 2010 Plan, reserved 2,500,000 shares that may be optioned or issued for all eligible participants.


June 30, 2012 and 2011
Stock Options	Number	Exercise Price	Term
Outstanding at Beginning of the Year	1,122,498	$3.55 - $5.00	5 Years
Cancelled options Options Outstanding at June 30, 2012	1,122,498

The Company had granted 20,000 options to a consultant in May 2009 for her work related to Proteoderm products. Of the 20,000 options, 10,000 were exercisable immediately with the remaining 10,000 exercisable upon completion of the consultant’s engagement. The options are to expire in five years.

The exercise price of the options is $2.50 per share. The options were valued utilizing the Black-Scholes method and have a put option value of $1.5395, calculated based on an expected term of 5 years, expected stock volatility of 100%, expected stock dividend yield of 0%, and risk-free interest rate of 3%. The value of the 10,000 options that are expensed in May 2009 is $15,395.

The Company had granted 15,000 options to a consultant in April 2010 for his work related to Proteoderm products. Of the 15,000 options, 5,000 were exercisable immediately with an additional 5,000 exercisable upon completion of certain requirements under the terms of the contract and the remaining 5,000 exercisable upon completion of the consultant’s engagement. The options are to expire in five years.

The exercise price of the options is $3.50 per share. The options were valued utilizing the Black-Scholes method and have a put option value of $2.6987, calculated based on an expected term of 5 years, expected stock volatility of 180.50%, expected stock dividend yield of 0%, and risk-free interest rate of 1.75%. The value of the 5,000 options that are expensed in April, 2010 is $13,494.

The Company had granted 1,000,000 options to its President, Michael Cohen, on April 26, 2010 exercisable immediately. The options are to expire in five years. These were issued pursuant to a license agreement for Stromal Cell. The exercise price of the options is $3.55 per share. The options were valued utilizing the Black-Scholes method and have a put option value of $3.4019, calculated based on an expected term of 5 years, expected stock volatility of 180.5%, expected stock dividend yield of 0%, and risk-free interest rate of 1.75%. The value of the 1,000,000 options that are capitalized as license on the condensed consolidated balance sheet is $3,401,891. These options are exempt for any stock splits or other reorganizations that would effect the option holder negatively.

The Company had granted 75,000 options to a U.S. based investor relations firm on June 1, 2010 exercisable ratably over 12 months commencing July 1, 2010. The options are to expire in five years. If Proteonomix cancels the contract after a three month trial period, then the maximum amount of options exercisable is 18,750. The Company has expensed six months of these options (37,500 total) that have vested through December 31, 2010 as stock based compensation in the amount of $72,507 as of December 31, 2010. There will be no further options vested as the contract was terminated.

The Company had granted 100,000 options to a European investor relations firm on June 15, 2010 exercisable ratably over 12 months commencing July 15, 2010. The options are to expire in June 2011. The Company has expensed six months of these options (49,998 total) that have vested through December 31, 2010 as stock based compensation in the amount of $96,673 as of December 31, 2010. There will be no further options vested as the contract was terminated.

March 31, 2012 and 2011
Stock Options	Number	Exercise Price	Term
Outstanding at Beginning of the Year	1,122,498	$3.55 - $5.00	5 Years
Cancelled options Options Outstanding at March 31, 2012	1,122,498

NOTE 10 -

PROVISION FOR INCOME TAXES

Deferred income taxes are determined using the liability method for the temporary differences between the financial reporting basis and income tax basis of the Company’s assets and liabilities. Deferred income taxes are measured based on the tax rates expected to be in effect when the temporary differences are included in the Company’s tax return.

Deferred tax assets and liabilities are recognized based on anticipated future tax consequences attributable to differences between financial statement carrying amounts of assets and liabilities and their respective tax bases. At ~~March~~June 3130, 2012, deferred tax assets consist of the following:

Net operating losses

$ 7,~~025~~311,~~932~~228

Valuation allowance

(7,~~025~~311,~~932~~228)

At ~~March~~June 3130, 2012, the Company had a net operating loss carry-forward in the amount of $20,~~664~~568,~~507~~345 available to offset future taxable income through 2032. The Company established valuation allowances equal to the full amount of the deferred tax assets due to the uncertainty of the utilization of the operating losses in future periods. A reconciliation of the Company’s effective tax rate as a percentage of income before taxes and federal statutory rate for the periods ended ~~March~~June 3130, 2012 and 2011 is summarized as follows:

~~March~~June 3130, 2012

~~March~~June 3130, 2011

Federal statutory rate

(34.0%)

State income taxes, net of federal benefits

3.3

Valuation allowance

30.7

2418

NOTE 11 -

FAIR VALUE MEASUREMENTS

OnFair ~~January~~value 1,is ~~2008,~~defined as the ~~Company~~exchange ~~adopted~~price ~~ASC~~that ~~820.~~would ~~ASC~~be ~~820~~received ~~defines fair value, provides a consistent framework~~ for ~~measuring~~an ~~fair~~asset ~~value~~or ~~under~~paid ~~generally~~to ~~accepted~~transfer ~~accounting~~a ~~principles~~liability ~~and~~in ~~expands~~the ~~fair~~principal ~~value~~or ~~financial~~most ~~statement~~advantageous ~~disclosure~~market ~~requirements.~~for ~~ASC~~the ~~820’s~~asset ~~valuation~~or ~~techniques~~liability ~~are~~in ~~based~~an onorderly ~~observable~~transaction ~~and~~between ~~unobservable inputs. Observable inputs reflect readily obtainable data from independent sources, while unobservable inputs reflect our~~ market ~~assumptions.~~participants ~~ASC~~on ~~820 classifies these inputs into~~ the ~~following~~measurement ~~hierarchy:~~date.

~~Level~~Valuation 1techniques ~~inputs:~~used ~~Quoted~~to ~~prices~~measure ~~for~~fair ~~identical~~value ~~instruments~~must inmaximize ~~active~~the ~~markets~~use of observable inputs and minimize the use of unobservable inputs. The fair value hierarchy is based on three levels of inputs, of which the first two are considered observable and the last unobservable, as follows:

Level 2 inputs: Quoted prices for similar instruments in active markets; quoted prices for identical or similar instruments in markets that are not active; and model-derived valuations whose inputs are observable or whose significant value drivers are observable.


	·	Level 1 – Quoted prices in active markets for identical assets and liabilities.
	·	Level 2 – Inputs other than Level 1 that are observable, either directly or indirectly, such as quoted prices for similar assets or liabilities, quoted prices in markets that are not active, or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities.

· Level 3 – Unobservable inputs: ~~Instruments~~that ~~with~~are ~~primarily~~supported ~~unobservable~~by little or no market activity and that are significant to the fair value ~~drivers~~of the assets or liabilities.

The table below categorizes assets and liabilities measured at fair value on a recurring basis as of June 30, 2012 and December 31, 2011:


	Fair Value		Fair value measurement using
	June 30, 2012		Level 1		Level 2		Level 3
Assets:
Money Market	$	2,164,934	$	2,164,934	$	–	$	–
						–		–
Total Assets	$	2,164,934	$	2,164,934	$	–	$	–
Liabilities:
Common stock warrant liability	$	405.052	$	–	$	–	$	405,052


	Fair Value		Fair value measurement using
	December 31, 2011		Level 1		Level 2		Level 3
Assets:
Money Market	$	-	$	-	$	–	$	–
						–		–
Total Assets	$	-	$	-	$	–	$	–

Liabilities:
Common stock warrant liability	$	-	$	–	$	–	$	-0-

The table below summarizes the activity of Level 3 inputs measured on a recurring basis for the three months ended March 31, 2012:


(in thousands)	Fair Value Measurements of Common Stock Warrants Using Significant Unobservable Inputs (Level 3)

Balance at December 31, 2011	$	-0-

Change in fair value of common stock warrant liability		405,052
Balance at March 31, 2012	$	405,052

(1) See, Note 6 – Common Stock Warrant Liability.

The significant unobservable inputs used in the fair value measurement of the common stock warrant are the historical volatility of our common stock market price, expected term of the applicable warrants, and the risk-free interest rate based on the U.S. Treasury yield curve in effect at the measurement date. In addition to the significant unobservable inputs noted above, the fair value measurement of the 2012 five-year warrants also takes into account the closing price of our common stock on the measurement date, and an assumption of the likelihood and timing of the occurrence of an event that would result in an adjustment to the exercise price in accordance with the anti-dilutive pricing provisions in the warrant. Any significant increases or decreases in the unobservable inputs, with the exception of the risk-free interest rate, would result in significantly higher or lower fair value measurements.


Significant Unobservable Input Assumptions of Level 3 Valuations	March 31, 2012			December 31, 2011

Historical Volatility		89% - 113	%
Expected Term (in years)		5
Risk-free interest rate		0.33% - 0.78	%

NOTE 12 - SEGMENT INFORMATION

The Company operates and the chief decision maker for the Company segregates the operations into five separate distinct reporting segments. These segments are the sperm bank division, the stem-cell division, and includes the minimal operating expenses of Proteoderm, the skin care products division, PRTMI, Thor and StromaCel.

Operating segment data for the ~~three~~six months ended ~~March~~June 3130, 2012 is as follows:

	Stem-Cell/Thor	Proteoderm	Sperm Bank (Discontinued)	PRTMI & PRTMI RD(1)	StromaCel/ XGen	Total
Sales	$ -	$ -	$2,290	$ -	$ -	$2,290
Cost of sales	$ -	$ -	$585	$ -	$ -	$585
Gross profit (loss)	$ -	$ -	$1,705	$ -	$ -	$1,705
Operating expenses	$2,~~124~~976,~~303~~536	$-	$-	$-	$-	$2,~~124~~976,~~303~~536
Depreciation and amortization	$918,~~535~~955	$ -	$ -	$ -	$~~85,047~~	$9418,~~582~~955
Other income (expense)	$263,~~395~~147,931	~~($925)~~	$ -	~~($37)~~	~~($446)~~	$243,~~987~~147,931
Net income (loss)	($23,~~107,443)~~04579	($~~925~~1,850)	$151,~~705~~678	($3775)	($85170,~~493~~810)	($2183,~~192,193~~523)
Segment assets	$42,~~034~~928,~~953~~079	$1201,500	$~~211,681~~-	$-	$2,~~749~~624,~~862~~675	$65,~~997~~754,~~996~~254
Fixed Assets, net of depreciation	$2031,~~773~~885	$ -	$ -	$ -	$ -	$2031,~~773~~885

(1)

PRTMI RD is a wholly-owned subsidiary of PRTMI.

Operating segment data for the ~~three~~six months ended ~~March~~June 3130, 2011 is as follows:

	Stem-Cell	Proteoderm	Sperm Bank	PRTMI & PRTMI RD(1)	StromaCel/ XGen	Total
	Stem-Cell/Thor	Proteoderm	Sperm Bank	PRTMI & PRTMI RD(1)	StromaCel/ XGen	Total
Sales	$ -	$ -	$811,~~165~~979	$ -	$ -	$811,~~165~~979
Cost of sales	$ -	$ -	$37,~~379~~161	$ -	$ -	$37,~~379~~161
Gross profit	$ -	$ -	$4,~~786~~818	$ -	$ -	$4,~~786~~818
Operating expenses	$~~170~~312,~~938~~262	$-	$2038,~~094~~087	$-	$-170,095	$~~191~~520,~~032~~444
Depreciation and amortization	$819,~~858~~189	$ -	$ -	$ -	$~~85,047~~-	$9319,~~905~~189
Other income (expense)	($1736,~~980~~053)	($~~914~~1,840)	$ -	($3774)	($~~442~~888)	($1938,~~373~~855)
Net income (loss)	($197,776)	($914)	($15,308)	($37)	($86,489)	($299,524)
Net (loss)	($367,054)	($1,840)	($33,269)	($74)	($170,983)	($573,670)
Segment assets	$~~275~~306,~~069~~738	$-	$~~208~~206,~~695~~341	$-	$3,~~090~~005,~~051~~004	$3,573,815
Fixed Assets, net of depreciation	$2927,~~641~~353	$ -	$ -	$ -	$ -	$2927,~~641~~353

(1)

PRTMI RD is a wholly-owned subsidiary of PRTMI.

25NOTE 13 – POTENTIAL COVENANT VIOLATION

~~NOTE~~In 13accordance with the Registration Rights Agreement, the Company failed to timely file their Registration Statement on Form S-1 ~~SUBSEQUENT~~five ~~EVENTS~~days after the filing of their Annual Report on Form 10-K. As a result, the Company is obligated to pay a penalty of 1.5% of the gross proceeds received. Gross proceeds amounted to $3,804,991, and 1.5% of those proceeds amounts to $57,075. This amount has been accrued.

On April 10, 2012, the University of Miami terminated the Research Agreement between the University and the Company by delivering written notice of the termination to the Company. The $105,000 that was paid by the Company were returned. The Company is currently interviewing other institutions to conduct this trial. 20

OnNOTE ~~April~~14 ~~24, 2012, the Company terminated the auditor~~ – ~~registrant~~SALE ~~relationship~~OF ~~with~~THE ~~KBL,~~SPERM ~~LLP,~~BANK ~~and~~OF ~~replaced~~NEW ~~KBL~~YORK, ~~LLP~~INC. ~~with~~/ ~~JPDH~~DISPOSITION &OF ~~Company on April 25, 2012.~~SUBSIDIARY

InEffective ~~accordance~~April ~~with~~1, ~~the Registration Rights Agreement~~2012, the Company ~~failed~~sold ~~to timely file~~ their ~~Registration~~operating ~~Statement~~subsidiary, onThe ~~Form~~Sperm ~~S-1~~Bank ~~five days after the filing~~ of ~~their~~New ~~Annual~~York, ~~Report~~Inc. onfor ~~Form~~forgiveness ~~10-K~~of debt. As a result, the ~~Company~~Sperm isBank ~~obligated~~of toNew ~~pay~~York, aInc. ~~penalty~~received ofall ~~1.5%~~remaining ofinventory ~~the~~and ~~gross~~outstanding ~~proceeds~~accounts ~~received~~receivable as of March 31, 2012. ~~Gross~~There ~~proceeds~~was ~~amounted~~no toactivity ~~$3,804,991,~~in ~~and~~April 12012 for this entity.5% The result of ~~those~~the ~~proceeds~~transaction ~~amounts~~was toa gain on disposal of $5710,~~075~~424.

~~The~~As ~~Company~~a ~~and~~result ~~its subsidiary The Sperm Bank~~ of ~~New~~this ~~York~~sale, ~~Inc.~~the ~~have~~Company ~~agreed that~~ effective April 301, 2012, ~~the~~became Company will sell back the shares owned in The Sperm Bank of New York, Inc. and any remaining assets of that entity to the former shareholder of The Sperm Bank of New York, Inc. in recognition of any liabilities The Sperm Bank of New York, Inc. and the Company owed to Biogenetics, Inc. and a ~~previous~~development ~~shareholder~~stage ~~had at that time. As a result of this transaction~~company, ~~this~~as ~~entity~~it ~~will~~continues ~~no longer be consolidated in~~ the ~~Company’s financials. Additionally, the Company may be considered to be in the~~ development ~~stage~~of ~~after~~its ~~this~~core ~~transaction is completed~~technology.

As a result of this transaction, the Company’s financial statements have been prepared with the results of operations and cash flows of this disposed entity shown as discontinued operations. All historical statements have been restated in accordance with GAAP. Summarized financial information for discontinued operations for the periods ended June 30, 2012 and 2011 are as follows:

Balance Sheet at March 31, 2012:

Cash

$ 13

Accounts receivable

20,763

Inventory

190,905

Accounts payable and accrued expenses (222,105)

Gain on disposition of SBNY

$ 10,424

Results of operations – June 30, 2012

Revenues

$ 2,290

Cost of revenues (585)

General and administrative -

Gain from discontinuing operations $ 1,705

Results of operations – June 30, 2011

Revenues

$ 11,979

Cost of revenues (7,161)

General and administrative (38,088)

Loss from discontinuing operations $ (33,270)

NOTE 15 - Subsequent events

Subsequent to the date of the financial statements, the Company entered into a license agreement with Ian McNiece, an officer and director of the Company, related to Stromal Cell Technology.

Subsequent to the date of the financial statements, the Company was served with a Complaint by ten of its fourteen investors in the Series E Preferred Stock offering, seeking damages for alleged contractual violations of the Registration Rights Agreement executed in the first quarter of 2012 and alleged misrepresentations related to the University of Miami clinical testing. With respect to the latter the Company has meritorious defenses and will vigorously defend the suit. The Company believes its liability for the contractual violations amounts to approximately $80,000.

Subsequent to the date of the financial statements, the Company sold the Sperm Bank of New York, Inc. to Albert Anouna, an unrelated party for forgiveness of debt. As a result, the Sperm Bank of New York, Inc. received all remaining inventory and outstanding accounts receivable as of March 31, 2012. There was no activity in April 2012 for this entity. The result of the transaction was a gain on disposal of $10,424.

Subsequent to the date of the financial statements, the Company filed an IND application with the FDA. On August 13, 2012, the Company received confirmation from the FDA that the Company would be allowed to proceed with the Phase I clinical trail of its UMK-121 combination drug therapy for ESLD patents.

ITEM 2. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

General

You should read the following summary together with the more detailed information and consolidated financial statements and notes thereto and schedules appearing elsewhere in this report. Throughout this report when we refer to the “Company,” “Proteonomix,” “we,” “our” or “us,” we mean Proteonomix, Inc., and its subsidiaries.

This discussion and analysis of our financial condition and results of operations is based upon our consolidated financial statements which have been prepared in accordance with accounting principles generally accepted in the United States. The preparation of these financial statements requires us to make estimates and judgments that affect the reported amounts of assets, liabilities, revenue and expenses, and related disclosure of contingent assets and liabilities. On an on-going basis, we evaluate our critical accounting policies and estimates, including those related to revenue recognition, intangible assets, and contingencies. We base our estimates on historical experience, where available, and on various other assumptions that we believe to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results may differ from these estimates under different assumptions and conditions.

Except for historical information, the material contained in this Management’s Discussion and Analysis is forward-looking. Our actual results could differ materially from the results discussed in the forward-looking statements, which include certain risks and uncertainties. These risks and uncertainties include the rate of market development and acceptance of our products, the unpredictability of our sales cycle, the limited revenues and significant operating losses generated to date, and the possibility of significant ongoing capital requirements.

Our independent registered public accounting firm’s report on the consolidated financial statements for the year ended December 31, 2011 contains an explanatory paragraph wherein they expressed an opinion that there is substantial doubt about our ability to continue as a going concern. Accordingly, careful consideration of such opinions should be given in determining whether to continue or become our stockholder.

We are a biotechnology company engaged in the discovery and development of cell therapeutics, tissue banking services and cosmeceutical products. Our technologies are embodied in patent applications including but not limited to: a medium and scaffolding for enhancing the growth of cells, a growth platform for cells, a device to eliminate malformed cells via filtration. We have developed products utilizing our intellectual property including but not limited to an anti-aging cosmeceutical based on our NC138 protein matrix UMK 121 and the StromaCel™ cardiac treatment. We have utilized our management and advisory team in conjunction with third party universities and research centers to develop these products and technologies. We have further developed an innovative business model for early commercialization and expedited FDA trials for our products and services through an international network of laboratories.

Company Overview

Cosmeceuticals – We have developed a range of anti-aging ~~and wound care~~ products, ~~that~~which we intend to manufacture, market and sell through our Proteoderm subsidiary based on a stem cell secreted matrix of proteins that stimulate collagen.

Cell Therapies – We are developing a diverse array of therapies for major diseases such as cardiac arrest and diabetes. Our first product, StromaCel™ cellular material for post-myocardial infarction patients that we intend to bring to FDA trials in 2012 in conjunction with our new cellular expansion technology. As of December 31, 2011 the Company has not filed an IND with the FDA for its StromaCel treatment. The Company intends to raise sufficient funds over the next twelve months in order to file such application with the FDA and to contract with third party to conduct such study and to retain the services of an IRB for such trial. Pre-clinical studies evidenced sufficient efficacy of similar cells used in StromaCel therapy to continue to pursue the utilization of the cells in a human clinical trial. The benefit of using the cells to treat post-myocardial infarction is the anti-inflammatory effect of StromaCel on damaged cardiac tissue.

Business Model – We are seeking to establish an international network of laboratories through which we intend to reach market early for treatments still in FDA trials while simultaneously expediting the FDA trials with the data collected from the treatment. As of December 31, 2012, we have not established any network of laboratories either domestic or international.

Pharmacological – Our first pharmacological product, currently named UMK 121, provides for the in vivo mobilization of specific bone marrow cells. The pre-clinical studies were conducted in rodents and a large animal model to confirm the potential of the UMK-121 technology to mobilize Stromal Stem Cells (“SSCs”) into the peripheral blood of animals, thereby making the SSCs available for therapeutic uses. The Company has created a wholly owned subsidiary, Thor Biopharma Inc. (“THOR”) to develop and commercialize the UMK 121. On April 10, 2012, the University of Miami terminated the Research Agreement between the University and the Company by delivering written notice of the termination to the Company. The $105,000 that was paid by the Company was returned. The Company is currently interviewing other institutions to conduct this trial.22

Pharmacological – Our first pharmacological product, currently named UMK 121, provides for the in vivo mobilization of specific bone marrow cells. The pre-clinical studies were conducted in rodents and a large animal model to confirm the potential of the UMK-121 technology to mobilize Stromal Stem Cells (“SSCs”) into the peripheral blood of animals, thereby making the SSCs available for therapeutic uses. The Company has created a wholly owned subsidiary, Thor Biopharma Inc. (“THOR”) to develop and commercialize the UMK 121. THOR had negotiated an agreement with the University of Miami on a human clinical trial of UMK-121, but this trial was terminated by the University in April, 2012. The Company is continuing to seek a new facility to conduct the trial.

Technology Overview

We have worked together with independent outside laboratories and national universities to develop a portfolio of complementary and synergistic technologies covering all steps in the Regenerative Therapy process. These steps include:

Cell Identification – Stem cells occur in various organs in the body, identifying the desired cells from all other cells is the first step towards a treatment. We have filed patent applications for biomarkers specifically identifying Islet Cells in the pancreas for diabetes treatment and Stromal Cells in bone marrow for cardiac treatment, marketed under the brand name StromaCel™.

Cell Isolation – Once the cells are identified, the desired cells must be isolated from all others to create a pure material to increase efficiency and reduce rejection. This is the second step towards a treatment. We have filed patents on a method of stem cell isolation for various applications.

Cell Conversion – For some treatments, the Stem Cells must be converted from one type to another. We have filed a patent for conversion of pancreatic stem cells into insulin producing beta cells as part of our diabetes research.

Cell Expansion – Once the desired cells have been identified, isolated, and converted for the desired result, the quantity must be dramatically increased in number. Current technology is generally limited to a five-generation increase in cells before differentiation (replication errors). We have developed a unique growth medium and matrix that currently shows many additional generations without differentiation. We have filed a patent application together with John Hopkins University and are currently prosecuting same. This technology is distinguished from other technologies in the manner in which the cells are replicated. The technology involves the utilization of a cellular platform rather than other technologies that involve a device, such as Pluristem Therapeutics PluriX™ three-dimensional process.

Cryopreservation – The final step in treatment is the preservation of the material for storage and transport. We have developed a technology that decreases the numbers of cells lost during the cryopreservation and thawing process and further reduces the chances of contamination.

Proteoderm, Inc.

We have developed cosmeceutical products based on patent applications of our stem cell derived proteins Matrix NC-138™ (“NC138") technology, which we have assigned to our subsidiary, Proteoderm. “Cosmeceutical" is a word blended from “cosmetic" and “pharmaceutical" and is defined as a cosmetic with active pharmaceutical ingredients. Proteoderm introduced our cosmeceutical at the Anti-Aging Conference sponsored by the American Academy of Anti-Aging Medicine held in National Harbor, Maryland in August, 2008 by manning a kiosk and providing samples of our cosmeceutical kits to participants, primarily physicians and industry leaders.

Proteoderm has developed an anti-aging kit consisting of a day cream, night cream, cleanser, ~~exfoliant~~exfoliator and under eye cream under the brand name “Matrix NC-138."

We anticipate that the cosmeceutical kits will be ready for shipment to customers as soon as the production process is complete, estimated, in the fourth quarter 2012. This launch was delayed due to inability to manufactureNC-138 due to lack of funds. We also recognized that we needed to have a INCI nomenclature, discussed herein below. Further, The Company also failed to complete a manufacturing agreement to produce the containers and packaging for its cosmeceutical line due to lack of sufficient funds. These impediments have been removed in large part and we anticipate signing the agreements to manufacture both the NC-138 and the packaging materials in the fourth quarter of 2012.

Proteoderm designs, produces and synthesizes proteins, and polypeptides (chains of linked amino acids which when folded in a particular three-dimensional configuration, become protein) secreted by stem cells and incorporate them into uniquely formulated personal care products. Its business concept is to develop and commercialize products based upon sophisticated, high performance biomaterials exclusively for use in the cosmetics and personal care markets. Our marketing and promotional efforts will feature the anti-aging and anti-wrinkle properties of our products formulated with NC-138. We believe that cosmeceuticals containing our Matrix NC 138 can be topically applied to consumers’ skin and can be taken up into the outer skin layers to enhance the natural formation of collagen.

In vivo studies using an emulsion containing 3% Matrix NC-138™ on where volunteers against a placebo in a half-face double blind study were reviewed. Volunteers were asked to apply the cream twice daily for six weeks on the crow feet area. Several parameters were analyzed after six weeks: skin profile, skin hydration and a self assessment on the product given by panelists through a questionnaire. 23

OnIn ~~the~~ex ~~basis of in~~ vivo studies, weusing ~~believe~~an ~~that~~emulsion ~~our~~containing ~~cosmeceutical~~3% ~~refines~~Matrix ~~skin~~NC-138™ ~~texture~~on ~~and~~where ~~gives~~volunteers ~~suppleness~~against toa ~~the~~placebo ~~skin~~in ~~thus contributing to~~ a ~~youthful~~half-face ~~look.~~double ~~However,~~blind ~~the~~study ~~research,~~were ~~data~~reviewed. ~~and~~Six ~~conclusions~~volunteers ~~regarding~~from ~~our~~New ~~cosmeceutical~~York, ~~have~~New ~~not~~Jersey ~~been independently verified~~ and ~~the~~Connecticut ~~merits~~were ofasked ~~our claims have not been subject~~ to ~~independent~~apply ~~evaluation by experts in~~ the ~~cosmeceutical~~cream ~~field.~~twice ~~The~~daily ~~results~~for ofsix ~~our~~weeks ~~efficacy~~on ~~tests~~the ~~have~~crow’s ~~based~~feet onarea. ~~observations~~Several ~~of and~~parameters ~~have~~were ~~not~~analyzed ~~yet~~after ~~been~~six ~~replicated.~~weeks: Inskin ~~addition~~profile, ~~there~~skin ~~are~~hydration noand ~~established~~a ~~standards~~self ~~for~~assessment ~~test~~on ~~procedures,~~the ~~methodology~~product orgiven ~~documentation~~ by ~~which~~panelists ~~companies~~through ~~marketing~~a ~~cosmeceuticals~~questionnaire. ~~must~~The ~~adhere~~studies ~~before~~were ~~making~~conducted ~~claims~~during ~~about~~2008 ~~their~~and ~~products' efficacy~~2009.

On the basis of the ex vivo studies, we believe that our cosmeceutical refines skin texture and gives suppleness to the skin thus contributing to a youthful look. We believe this from a totally subjective consideration of the aesthetic appearance of the subjects. However, the research, data and conclusions regarding our cosmeceutical have not been independently verified and the merits of our claims have not been subject to independent evaluation by experts in the cosmeceutical field. The results of our efficacy tests have based on observations of and have not yet been replicated. In addition, there are no established standards for test procedures, methodology or documentation by which companies marketing cosmeceuticals must adhere before making claims about their products' efficacy.

The Personal Care Products Council (“PCPC"), formerly known as the “Cosmetic, Toiletry and Fragrance Association,” is a leading national trade association for the cosmetic and personal care products industry. It is a trusted source of information for and about the industry and a vocal advocate for consumer safety and continued access to new, innovative products. The PCPC has adopted a Consumer Commitment Code to formalize many existing product safety practices and to demonstrate its members’ commitment to safety. The PCPC does not regulate but provides information on national and international regulation. We have applied to the PCPC. We presently adhere to the Personal Care Products Council Consumer Commitment Code, including filing timely reports with the FDA regarding manufacturing and ingredient usage, and will continue to do so after our membership application is accepted. However there is no penalty for failure to follow the code.

The following principles summarize the code: A company should market cosmetic products only after ensuring that every ingredient and finished product has been substantiated for safety and concentrating whether through the CIR or other appropriate data and information, including adverse events, should be available for inspection by the FDA and should maintain a safety information summary of ingredient and product safety information.

The Cosmetic Ingredient Review (“CIR") Expert Panel is an independent, nonprofit panel of scientists and physicians established in 1976 to assess the safety of ingredients used in cosmetics in the U.S. with the support of the U.S. Food and Drug Administration and the Consumer Federation of America in an open, unbiased, and expert manner, and to publish the results in the peer-reviewed scientific literature. The CIR is now an independent organization, the mission of which is to review and assess the safety of ingredients used in cosmetics in an open, unbiased, and expert manner, and to publish the results in the peer-reviewed scientific literature. Although funded by the PCPC, CIR and the review process are independent from the Council and the cosmetics industry. General policy and direction are given by a six member Steering Committee chaired by the President and CEO of the PCPC, with a dermatologist representing the American Academy of Dermatology, a toxicologist representing the Society of Toxicology, a consumer representative representing the Consumer Federation of America, an industry scientist (the current chair of the PCPC CIR Committee), and the PCPC Executive Vice President for Science.

We filed an application to the CIR for our proprietary Matrix NC-138 and it was recently approved. All other ingredients are on the approved list. These ingredients include water, a sun block, oils, thickening agents, moisturizers and fragrances. The approved list of cosmetic ingredients may be found at http://www.cir-safety.org/staff_files/pdf4.pdf.

The CIR Procedures established an Expert Panel to set priorities and review and assess ingredient safety data. The seven CIR Expert Panel voting members are physicians and scientists who have been publicly nominated by consumer, scientific, and medical groups; government agencies; and industry. Expert Panel members must meet the same conflict of interest requirements as individuals serving on FDA advisory committees. Three liaison members serve as nonvoting members representing government, consumers, and industry. With participation of these liaison representatives from FDA, CFA, and the Council, the CIR Expert Panel creates a unique forum for open discussions on issues affecting public safety.

CIR staff members conduct extensive literature searches, compile data, and prepare draft reports on high-priority ingredients. They organize the literature into several categories: chemistry (including physical properties and manufacture), use (cosmetic and non-cosmetic), general biology (with absorption, distribution, metabolism, and excretion data), and animal toxicology (acute, short-term, subchronic, and chronic studies, as well as dermal irritation and sensitization data).

The staff also prepares a clinical assessment of the ingredients that may include epidemiologic studies, along with classic repeated insult patch tests. In vitro test data are also gathered and incorporated into the review.

At each stage of the process, CIR seeks the input of all interested parties during a formal 60-day comment period.

If the open scientific literature contains insufficient information, the Expert Panel will call on industry or other interested parties to provide unpublished data or to undertake specific studies. After multiple opportunities for public comment and open, public discussion, a final safety assessment is issued.

The Panel may make one of four basic decisions regarding an ingredient:

Safe ingredients . Ingredients safe in the practices of use (product categories) and concentrations of use for each product category as documented in the safety assessment.

Unsafe ingredients. These are ingredients with specific adverse effects that make them unsuitable for use in cosmetics.

Safe ingredients, with qualifications. The Panel may reach the conclusion that an ingredient can be used safely, but only under certain conditions. Qualifications frequently relate to maximum concentration, but may also address rinse-off versus leave-on uses and other restrictions.

Ingredients for which the data are insufficient. If the Panel reaches an insufficient data conclusion, it does not state whether the ingredient is safe or unsafe. The Panel is, however, describing a situation in which the available data do not support safety. The specific data that would allow the Panel to complete its assessment always are identified.

CIR safety assessments are made available as monographs and are published in the International Journal of Toxicology. Each year, CIR publishes the CIR Compendium, a comprehensive collection of findings from all CIR reports.

Recognizing that new information may be available on safety assessments completed years ago, the Expert Panel may re-review of assessments that are more than 15 years old or for which there is some new information known to the Panel. If there are relevant new data, the Panel will consider the need for an amended safety assessment. If the search for newly available data fails to uncover information relevant to ingredient safety, or if the new data duplicate information already in the safety assessment, the Expert Panel will not reopen the safety assessment.

Although we believe that the results of our preliminary ex vivo studies are determinative of the efficacy of our cosmeceutical, we plan to perform a more formal and more extensive study for marketing purpose. The multi-center efficacy study is on a larger scale than previous tests we have conducted of the effects of the Proteoderm skin care line on aged skin, particularly wrinkles. The study is designed as a split-face study (i.e. one half the face using our cosmeceutical and the other the creams or lotions presently used by the participants in the study), conducted over the course of a twelve-week period for 150 patients. We anticipate that the study will commence as soon as shipment of product begins as we anticipate having a sufficient number of cosmeceutical kits and other materials for the test. We plan to ship our kits to customers prior to the completion of the study.

The study participants will be photographed immediately prior to commencement of the study, and every two weeks thereafter. Study Materials are expected to total 30-40 pages, including, but not limited to:

patient and Investigator questionnaires;

patient consents (subject to approval of the Company’s counsel);

instructions to patients and to investigators;

written agreements of the Investigators to participate in the Study;

study protocol (design of the Study);

patient logs; and

patient assessment forms.

Competition

While we are unaware of any companies that have cosmeceutical technologies similar to the ones we have developed, there are a substantial number of companies are offering anti-aging cosmetics. Many physicians offer Botox and laser therapies. ~~None of them includes a protein such as our patent pending protein, NC-138, which occurs in women during pregnancy.~~ Pending the outcome of further testing of our cosmeceutical, we are not claiming that our cosmeceutical has more advantageous anti-aging properties than other products. Many companies claim to offer “stem-cell related” products but none that we ~~believe~~are ~~that~~aware ~~none~~of have obtained CIR INCI name as a new compound.

The University of Miami had entered into an exclusive agreement with us to manufacture Matrix NC-138^TM as a product for our subsidiary Proteoderm.. The agreement with University of Miami has expired and we were negotiating an extension.. However, the relationship with the University of Miami ended in April 2012 and the Company is now seeking other manufacturing facilities. There can be no assurance that a manufacturing agreement will be executed, or if executed, performed.

Thor Biopharma, Inc.

On January 3, 2011 the Company formed a new subsidiary, Thor BioPharma, Inc., in order to provide an entry into the pharmaceutical market. On March 2, 2011, The Company entered into an agreement with The Cohen McNiece Foundation, Inc. (the "Foundation"), a Florida not-for-profit corporation, to exclusively develop and license the Foundation's UMK-121 Mobilization of Bone marrow Stem Cell technology ("UMK-121") which is a proprietary technology based upon existing FDA approved drugs. The License imposes no upfront costs on the Issuer, which will sublicense UMK-121 to its wholly owned subsidiary Thor BioPharma. The Issuer is required to make milestone payments to the Foundation upon 1) the issuance of a patent requiring payment to the Foundation of 50,000 shares of the Company’s common or $100,000 at the option of the Foundation, 2) completion of Phase III trials requiring payment of $200,000 to the Foundation and 3) commercialization which will require the payment of a 3% royalty on net sales. This License may be terminated for any of the following: Foundation has the right to terminate the License, upon written notice, in the event the Company breachs the obligation to pay the above described payments due upon issuance of a patent or the $200,000 due upon completion of a Phase III trial, but the Company has thirty (30) days to cure a breach of non-payment upon notice; or in the event of breach by the Company of any obligation to pay the 3% royalties or if assigned 3% of all payments received by the Company from the assignee; or in the event of any other breach by either Party, the Parties shall have all ordinary recourse to the legal system to enforce this agreement; or the Company has the right to terminate this Agreement by providing ninety (90) days written notice of its intent to terminate this Agreement to Foundation with or without cause. In the event of termination, such termination shall be without prejudice to Foundation's right to recover all amounts accruing to the Foundation prior to such termination and cancellation. Except as otherwise provided, should this Agreement be terminated for any reason, the Company shall have no rights, express or implied, under any patent property which is the subject matter of this Agreement, nor have the right to recover any royalties paid to the Foundation.. Upon termination, the Company shall have the right to dispose of Licensed Products then in its possession and to complete existing contracts for such products, so long as contracts are completed within six (6) months from the date of termination, subject to the payment of royalties to the Foundation. The term of the License commences upon the Effective Date of the Agreement and continue until the expiration, worldwide, of all of the Patent Rights.

On April 7, 2011, the Company announced that it filed a provisional patent application in anticipation of commencement of its initial clinical trial of a drug combination thought to extend life expectancy for a class of terminally ill patients awaiting liver transplants. The Company, based upon its exclusive license agreement to develop Mobilization of Bone Marrow Stem Cells Technology (UMK-121), filed a patent application in April 2011, covering mobilization of non-hematopoietic stem cells for applications in regenerative medicine.

29The Company and the University of Miami entered into a contract toward the end of 2011 to conduct a human clinical trial of UMK-121 on End Stage Liver Disease patients. The Company expects this trial to commence in February, 2012. The Company believes that the technology has applications in treating kidney, cardiac and lung diseases as well although very little work has been done in those areas.

The Company and the University of Miami entered into a contract toward the end of 2011 to conduct a human clinical trial of UMK-121 on End Stage Liver Disease patients. On April 10, 2012, the University of Miami terminated the Research Agreement between the University and the Company by delivering written notice of the termination to the Company. The $105,000 that was paid by the Company was returned. The Company is currently interviewing other institutions to conduct this trial. The Company believes that the technology has applications in treating kidney, cardiac and lung diseases as well although very little work has been done in those areas.

StromaCel, Inc.

In an effort to place different technologies and therapies in different subsidiaries, Stromacel, Inc. ("StromaCel") was registered as a Florida corporation on December 24, 2009 by our President and CEO, Michael Cohen, for $168. In February, 2010 we acquired all of StromaCel’s authorized shares at cost for $168 and StromaCel became a subsidiary of the Company.

StromaCel intends to develop therapies using stromal cells, which are key components of tissues and provide critical cytokines and growth factors as well as the cellular microenvironment for normal homeostasis. A cytokine is a small protein released by cells that affects the interactions and communications between cells and the behavior of cells. A growth factor is a naturally occurring substance capable of stimulating cellular growth, proliferation and differentiation. Homeostasis is a self-regulating process by which a biological system maintains stability while adjusting to changing conditions. Stromal cells provide a niche proliferation environment for stem cells. StromaCel's goal is to study the basic cellular properties of stromal cells and to identify the utility of cellular and protein derivatives in disease repair.

With the above in mind, on May 4, 2010, Proteonomix licensed from the ~~Cohen-~~McNiece-Cohen Foundation the Stromal Cell technology (“Technology”) for potential therapeutic use in the regrowth of damaged cardiac cells after a heart attack. The ~~Cohen-~~McNiece-Cohen Foundation was formed by Proteonomix President, Michael Cohen, and its Chief Scientific Officer and Vice-President, Ian McNiece, PhD to develop cellular technology for patients who have suffered myocardial infarctions. The ~~Technology~~term ~~was~~of ~~licensed~~this inLicense ~~exchange~~commenced ~~for~~May a4, 2%2010 ~~royalty~~and, onunless ~~gross~~sooner ~~revenue~~terminated, ~~derived~~terminates ~~from~~as ~~use~~to ofindividual ~~the~~patent ~~Technology~~rights ~~and~~in ~~1,000,000~~each ~~stock~~jurisdiction ~~options~~where atsuch ~~$3.55~~rights ~~per~~may ~~share~~exist toupon ~~Michael~~the ~~Cohen,~~expiration of the ~~Company’s~~patent ~~president~~rights in each individual country. ~~The~~ 2%Upon ~~royalty~~expiration ~~will~~in bea ~~used~~given byjurisdiction, ~~the~~Proteonomix ~~Foundation~~shall continue to dohave ~~further~~a ~~research~~license ~~into~~on ~~stem~~the ~~cell~~same ~~applications.~~terms ~~Proteonomix~~as ~~received~~prior ato ~~right~~patent ofexpiration, ~~first~~except ~~refusal~~that tosuch license ~~any~~shall ~~technology~~be ~~developed~~fully bypaid, perpetual, irrevocable and nonexclusive. To date no payments have been made to the Foundation. pursuant to this License.

Proteonomix has sub-licensed the Technology to StromaCel for a 2% royalty, but Proteonomix will remain responsible for all costs associated with patent prosecution for the Technology. In the event of bankruptcy, the rights to the Technology granted by the license revert to the Foundation. On February 1, 2011 the Company announced that it has filed an additional patent on the StromaCel technology that was intended to improve the Company's patent position on StromaCel with respect to a newly developed breakthrough method of stem cell expansion.26

The Technology was licensed in exchange for a 2% royalty on gross revenue derived from use of the Technology and 1,000,000 stock options at $3.55 per share to Michael Cohen, the Company’s president. The 2% royalty will be used by the Foundation to do further research into stem cell applications. Proteonomix received a right of first refusal to license any technology developed by the Foundation. Proteonomix has sub-licensed the Technology to StromaCel for a 2% royalty, but Proteonomix will remain responsible for all costs associated with patent prosecution for the Technology. Otherwise, there are no milestone payments contemplated in the License Agreement. Each Party shall has the right to terminate this Agreement upon thirty (30) days' written notice to the other upon the occurrence of any of the following:

(a)

Upon or after bankruptcy, insolvency, dissolution or winding up or assignment for the benefit of creditors of the other Party (other than a dissolution or winding up for the purpose of reconstruction or amalgamation) or a petition is filed for any of the foregoing and is not removed within ninety (90) days; or

(b)

Upon or after the breach of any material provision of this Agreement by the other Party, including, with respect to Proteonomix if the breaching Party has not cured such breach within the thirty (30) day period following written notice of termination by the non-breaching Party.

7.3

Dispute Resolution. Notwithstanding anything in this Section 7.3 to the contrary, to the extent Proteonomix reasonably and in good faith disagrees with any assertion by the Licensor that there has been a material breach or material default of this Agreement by Proteonomix, and Proteonomix provides written notice to the Licensor of its disagreement and the basis for its belief within fifteen (15) days after Proteonomix receives notice from the Licensor of a breach under this Section 7.3, this Agreement will remain in effect and any termination of this Agreement under Section 7.3 will be suspended pending resolution of such disagreement between the Parties.

7.4

Effect of Termination; Surviving Obligations.

(a)

Upon termination of this Agreement, all rights and obligations of the Parties under this Agreement shall terminate, except as set forth in this Article.

(b)

Upon termination of this Agreement by Proteonomix all rights to the Licensed Technology and the Licensed Patents shall revert to the Licensor.

(c)

In the event that the license granted to Proteonomix is terminated in accordance with this Article, any existing sublicenses granted by Proteonomix shall remain in effect and shall be automatically assigned by Proteonomix to the Licensor so that such sublicenses shall become direct licenses between the Licensor and the applicable Sublicensees on the terms set forth herein.

(d)

Expiration or termination of this Agreement shall not relieve the Parties of any obligation accruing prior to such expiration or termination. Except as expressly set forth elsewhere in this Agreement, the obligations and the rights of the Parties under Articles 5, 6, 7, 8 and 9 shall survive expiration or termination of this Agreement.

The licensed technology utilizes human Stromal Stem Cells (“SSC”) derived from mesenchymal stem cells, also referred to as MSCs. SSCs can selectively differentiate, based on the tissue environment, into various tissue lineages such as bone, muscle, fat, tendon, ligament, cartilage and bone marrow stroma. In addition, SSCs have anti-inflammatory properties and can prevent fibrosis or scarring. These characteristics give SSCs the potential to treat a wide variety of medical conditions.

In the event of bankruptcy, the rights to the Technology granted by the license revert to the Foundation. On February 1, 2011 the Company announced that it has filed an additional patent on the StromaCel technology that was intended to improve the Company's patent position on StromaCel with respect to a newly developed breakthrough method of stem cell expansion. During August 2012, the McNiece Cohen Foundation, Inc., Stromacel, Inc. and PRTMI were reinstated in the State of Florida, all of them having gone inactive due to nonpayment of franchise taxes. Being reinstated no issues are believed to exist regarding on-going business operations including, retention of the stromal cell technology currently licensed to StromaCel by the McNiece Cohen Foundation, Inc. continued development and license of UMK-121 by the Foundation; and continued development of our translational medicine business under PRTMI.

On June 18, 2012, the Company entered into an Exclusive License Agreement with Ian McNiece, the Company’s Chief Scientific Officer (the “Licensor”). Under the terms of the Exclusive License Agreement, the Licensor hereby grants to the Company an exclusive, worldwide, royalty bearing license, with the right to grant sublicenses to the Technology, Licensed Products, Licensed Improvements and Patents as noted in the agreement.

The Company will pay the Licensor the amounts set forth herein upon the first occurrence of each of the following milestone events: (1) License fee (upon execution of the agreement) - $100,000; (2) Agreement with a third party related to this technology - $250,000 and 50,000 shares of common stock; (3) Successful patent issue - $50,000; (4) Isolation of the active factor for tumor inhibition - $50,000; (5) Initiation of the Phase I clinical trial of the Licensed Products - $100,000; and (6) Grant by or marketing approval of the Licensed Product in the US (FDA) or Europe - $500,000.

Upon the First Commercial Sale of Licensed Product, the Company shall pay to the Licensor a royalty of three percent (3%) of Net Sales of a Licensed Product during the Royalty Term, as described therein. In addition, the Company shall pay to Licensor an amount equal to three percent (3%) of the Sublicense Fee received from any Sublicense.

Cord Blood Model

We have developed a Cord Blood expansion technology and combined it with an improved Cryopreservation system. These technologies may make it possible to change the standard model for Cord Blood Banking. Under our model, Umbilical Cord Blood banking will become a free service to patients and we will increase the donor supply to eliminate shortages. Once we can complete our trials (pre clinical and FDA), we will use our expansion and cryopreservation system to increase the number of usable cells in a donated cord blood unit; and offer a free service to process, cryopreserve and bank one dose per patient for the patient’s lifetime. The patient must, however, agree to donate all additional doses to transplant patients and parents are given an opportunity to protect their child (patient). At this time the ~~Company~~company ~~may~~does not believe that it will pursue the development of its Cord Blood Banking Model.

Regenerative Translational Medicine

Regenerative medicine refers to research into treatments that restore adult body parts. There are three strategies for future treatments: the injection of stem cells or progenitor cells; the induction of regeneration by introduced substances; and the transplantation of in vitro grown organs and tissues.

Translation Medicine is the emerging view of medical practice and interventional epidemiology, as a natural 21^st century progression from Evidence-Based Medicine. It integrates research inputs from the basic sciences, social sciences and political sciences to optimize both patient care and also preventive measures which may extend beyond the provision of healthcare services.

Translational Research is the underlying basis for Translational Medicine that is the process which leads from evidence based medicine to sustainable solutions for public health problems. Fulfilling the promise of translational research for improving the health and longevity of the world’s population depends on developing broad-based teams of scientists and scholars who are able to focus their efforts of clinical trials into changes in clinical practice, informed by evidence from the social and political sciences.

We formed Proteonomix Regenerative Translational Medicine Institute, Inc. ("PRTMI") as a Florida corporation on January 5, 2010 and PRTMI RD, SRL incorporated under the laws of the Dominican Republic in February, 2010 as a subsidiary of PRTMI. PRTMI will focus on the translation of promising research in stem cell biology and cellular therapy to clinical applications of regenerative medicine. At present, the PRTMI subsidiary does not have any assets, including technology licenses. We cannot guarantee if and when it will become operational.

XGen Medical LLC

On August 6, 2010 the Company formed a new subsidiary XGen Medical LLC, a Nevis Islands entity (“XGen Medical” or “XGen”). XGen Medical was established with the intention of conducting business in the global medical marketplace. Proteonomix planed on utilizing XGen Medical to serve as a platform for joint ventures with medical facilities worldwide. It was anticipated that new relationships formed with XGen Medical would create medical facilities capable of not just attracting treatments locally, but also acting as hubs for medical tourism. The establishment of a separate subsidiary, XGen Medical LLC., was useful in order to allow Proteonomix to properly enter global markets with the intention of soliciting business through our proprietary PRTMI model. Under an agreement, two investors were responsible for investing $5,000,000 into XGen Medical in exchange for a 49% interest in XGen Medical. In exchange for the investment StromaCel was to provide XGen Medical with the technology to practice the cardiac treatment utilizing the technology, and Proteoderm granted distribution rights to cosmeceuticals containing the proprietary stromal cell cosmetic technology in the GCC countries. Due to a default by one of the investors, the remaining investor has indicated that payments toward satisfaction of the contract will be made. To the date of this filing no such payments have been made. The Company plans on litigating to the fullest extent of the law to collect this investment along with any penalties incurred in the default. The negotiations with the second investor failed and the counterparties to the XGen Medical Agreements breached their contract responsibilities. We have assumed one hundred percent (100%) ownership of XGen Medical and are contemplating legal actions against both Patrizio Shawal Pilati and Valentina Earp-Jones, the counterparties to the XGen Medical Agreement. The minority shareholders that are in default will be pursued by all legal means.

Sperm Bank of New York

Reproductive Tissue Storage

The Sperm Bank of NY (“SBNY”) is principally engaged in the processing and cryogenic storage of Sperm. SBNY stores over 2,000 units of Sperm specimens. The specimens are stored in commercially available cryogenic storage units in a third party facility in Mountainside, NJ

Reproductive Tissue Storage

SBNY offers high quality and competitively priced reproductive tissue services that will include short and longer-term cryogenic storage, inter-facility transportation coordination, and special quarantined cryogenic storage for infectious disease positive specimens.

The reproductive tissue storage intends to assure clients of enhanced security for their family’s current and future biological tissue cryogenic storage needs. Reproductive tissue storage is also expected to assist clients with the facilitation of future possibilities available for their cryopreserved specimens, including donation for research, anonymous or direct donation.

Marketing

Marketing Approach

SBNY does not have an active Marketing program for its services and relies on Physician referral to obtain clients

Competition

SBNY believes that growth in the number of Sperm Cryo- Preservation facilities has subsided in the last few years. SBNY competes against many other local and national private sperm Banks. These competitors may have access to greater financial resources.

Government Regulation

SBNY is required to register with the State of New York and is subject to inspections by the state. As of December 31, 2011 SBNY was in compliance with its New York State regulatory requirements.

Federal and state laws govern SBNY’s ability to obtain and, in some cases, to use and disclose data that we may need to conduct certain activities. The Health Insurance Portability and Accountability Act of 1996 (“HIPAA”) requires the Department of Health and Human Services to issue a series of regulations establishing standards for the electronic transmission of certain health information. SBNY is not subject to HIPAA because SBNY does not engage in certain electronic transactions related to the reimbursement of healthcare providers and because tissue procurement and banking activities are exempt. However, the healthcare providers that collect sperm for SBNY’s customers are subject to HIPAA. The identifiable information shared is only what is permitted by HIPAA. In 2009, a portion of the American Recovery and Reinvestment Act of 2009 modified HIPAA under the Health Information Technology for Economic and Clinical Health Act (“HITECH Act”). While SBNY is still not subject to HIPAA for the reasons stated above SBNY may incur material expenses associated with compliance efforts. In addition, compliance may require management to spend substantial time and effort on compliance measures. If SBNY fails to comply with HIPAA, it could suffer criminal and civil penalties. The civil penalties could include monetary penalties ranging from $100 per violation to $1.5 million depending on the level of violation.

SBNY may also subject to local, state and federal laws and regulations relating to safe working conditions, laboratory and manufacturing practices and the use and disposal of hazardous or potentially hazardous substances. These laws include the Occupational Safety and Health Act (“OSHA”), Environmental Protection Agency (“EPA”), and those of the local Department of Health.

Enacted in 1970, OSHA requires all employers to assure safe and healthful working conditions for working men and women through development and implementation of work standards, education, and training. OSHA enforces the standards developed under the Act, applicable to all employers in the U.S. and its territories.

The Environmental Protection Agency (EPA) governs the management and proper disposal of products and by-products or waste. These products must be disposed in a manner that does not adversely affect the environment from which it came or where disposed of. The Department of Health on the local level primarily regulates systems and associated equipment employed in recovery activities such as back-up generators; therefore, governing specific internal processes.

Evolving legislation and regulations governing sperm banking in various jurisdictions throughout the world may impact SBNY.

Sale of the Sperm Bank of New York

In April 2012, the Company sold the Sperm Bank to Albert Anouna, an unrelated party who owned Biogenetics and who had assisted the Company in operating the Sperm Bank since 2006. The sale price was the assumption of the liabilities owed to Mr. Anouna by the Company and the Sperm Bank in the amount of $222,105. The Sperm Bank was sold because it had incurred operating losses for several years and the capital needed to increase revenue was determined to have been better spent on our stem cell therapies and cosmetic products.

History of the Company

Azurel, Ltd. was incorporated on June 26, 1995 in the State of Delaware and marketed a line of fragrances. On February 2, 2001, Azurel filed a voluntary petition for protection from creditors under Chapter 11 in the United States Bankruptcy Court for the District of New Jersey, Newark until it was discharged from bankruptcy in December, 2005. In September 2006, Azurel, Ltd., through a share exchange agreement, acquired National Stem Cell Inc. and its subsidiary, The Sperm Bank of New York and changed its name to National Stem Cell Holding, Inc.

~~National~~This ~~Stem~~trial ~~Cell~~was ~~had~~to ~~intellectual~~commence ~~property~~in ~~consisting~~the first quarter of ~~research~~2012. ~~into~~On ~~immunological~~April ~~isolation~~10, 2012, the University of ~~stem~~Miami ~~cell~~terminated ~~populations~~the ~~derived~~Research ~~from~~Agreement ~~umbilical~~between ~~cord~~the ~~blood~~University and ~~bone~~the ~~marrow~~Company ~~and,~~by indelivering ~~March~~written ~~2006~~notice of the termination to the Company. The $105,000 ~~began~~that ~~working~~was ~~with~~paid by the ~~John~~Company ~~Hopkins~~was ~~University~~returned. This ~~and~~trial ~~developed~~was ~~multiple~~terminated ~~patents~~by inthe ~~stem~~University ~~cell~~in ~~expansion~~April, ~~stem~~2012. ~~cell~~The ~~growth~~Company ~~and~~is ~~identification~~continuing ofto ~~particular~~seek ~~types~~a ofnew ~~stem~~facility ~~cells~~to conduct the trial.

The ~~Sperm~~Company ~~Bank~~believes ofthat ~~New~~the ~~York,~~technology anhas ~~operating~~applications ~~wholly-owned~~in ~~subsidiary~~treating ~~of National Stem Cell~~kidney, ~~derives~~cardiac ~~its~~and ~~revenue~~lung ~~from~~diseases ~~the~~as ~~sale~~well ofalthough ~~donated~~very ~~sperm~~little ~~units~~work tohas ~~potential~~been ~~parents~~done ~~and~~in ~~from~~those ~~the cryopreservation of sperm units maintained by individuals for future use~~areas.

On ~~July~~June 818, ~~2008~~2012, the Company ~~formed~~entered ~~Proteoderm~~into asan aExclusive ~~third~~License ~~wholly-owned~~Agreement ~~subsidiary~~with Ian McNiece, the Company’s Chief Scientific Officer (the “Licensor”). ~~Through~~Under ~~this~~the ~~subsidiary~~terms of the Exclusive License Agreement, the Licensor hereby grants to the Company ~~produces~~an ~~and~~exclusive, ~~synthesizes~~worldwide, ~~protein~~royalty ~~polypeptides~~bearing ~~secreted~~license, bywith ~~stem~~the ~~cells~~right ~~and~~to ~~incorporate~~grant ~~them~~sublicenses ~~into~~to ~~uniquely~~the ~~formulated~~Technology, ~~personal~~Licensed ~~care~~Products, ~~products~~Licensed Improvements and Patents as noted in the agreement.

InThe ~~August~~Company ~~2008,~~will pay the ~~Company~~Licensor ~~changed~~the ~~its~~amounts ~~name~~set forth herein upon the first occurrence of each of the following milestone events: (1) License fee (upon execution of the agreement) - $100,000; (2) Agreement with a third party realted to ~~Proteonomix~~this technology - $250,000 ~~Inc~~and 50,000 shares of common stock; (3) Successful patent issue - $50,000; (4) Isolation of the active factor for tumor inhibition - $50,000; (5) Initiation of the Phase I clinical trial of the Licensed Products - $100,000; and (6) Grant by or marketing approval of the Licensed Product in the US (FDA) or Europe - $500,000. The $100,000 was paid in June, 2013.

InUpon anthe ~~effort~~First toCommercial ~~place~~Sale ~~different~~of ~~technologies~~Licensed ~~and~~Product, ~~therapies~~the inCompany ~~different~~shall ~~subsidiaries,~~pay ~~Stromacel,~~to ~~Inc.~~the ~~("StromaCel")~~Licensor ~~was~~a ~~registered~~royalty asof athree ~~Florida~~percent ~~corporation~~(3%) onof ~~December~~Net ~~24,~~Sales ~~2009~~of bya ~~our~~Licensed ~~President~~Product ~~and~~during ~~CEO,~~the ~~Michael~~Royalty ~~Cohen~~Term, ~~for~~as ~~$168~~described therein. In ~~February~~addition, ~~2010~~the weCompany ~~acquired~~shall ~~all~~pay ofto ~~StromaCel’s~~Licensor ~~authorized~~an ~~shares~~amount atequal ~~cost~~to ~~for~~three ~~$168~~percent ~~and~~(3%) ~~StromaCel~~of ~~became~~the aSublicense ~~subsidiary~~Fee ofreceived ~~the~~from ~~Company~~any Sublicense.

StromaCel intends to develop therapies using stromal cells which are key components of tissues and provide critical cytokines and growth factors as well as the cellular microenvironment for normal homeostasis. A cytokine is a small protein released by cells that affects the interactions and communications between cells and the behavior of cells. A growth factor is a naturally occurring substance capable of stimulating cellular growth, proliferation and differentiation. Homeostasis is a self-regulating process by which a biological system maintains stability while adjusting to changing conditions. Stromal cells provide a niche proliferation environment for stem cells. StromaCel's goal is to study the basic cellular properties of stromal cells and to identify the utility of cellular and protein derivatives in disease repair.

With the above in mind, on May 4, 2010, Proteonomix licensed from the Cohen-McNiece Foundation the Stromal Cell technology (“Technology”) for potential therapeutic use in the regrowth of damaged cardiac cells after a heart attack. The Cohen-McNiece Foundation was formed by Proteonomix President, Michael Cohen, and its Chief Scientific Officer and Vice-President, Ian McNiece, PhD to develop cellular technology for patients who have suffered myocardial infarctions. The Technology was licensed in exchange for a 2% royalty on gross revenue derived from use of the Technology and 1,000,000 stock options at $3.55 per share to Michael Cohen, the Company’s president. The 2% royalty will be used by the Foundation to do further research into stem cell applications. Proteonomix received a right of first refusal to license any technology developed by the Foundation. Proteonomix has sub-licensed the Technology to StromaCel for a 2% royalty, but Proteonomix will remain responsible for all costs associated with patent prosecution for the Technology. In the event of bankruptcy, the rights to the Technology granted by the license revert to the Foundation. On February 1, 2011 the Company announced that it has filed an additional patent on the StromaCel technology that was intended to improve the Company's patent position on StromaCel with respect to a newly developed breakthrough method of stem cell expansion.

On June 1, 2010, Proteonomix began to concentrate its Research and Development resources on the development of StromaCel in order to further develop its portfolio of intellectual properties and global partnerships.

On May 24, 2010, Proteonomix launched its retail web site, www.proteoderm.com, and began accepting pre-orders for its anti-aging line of skin care products. Proteoderm contains Matrix NC-138 an anti-aging bioactive ingredient, developed by Proteonomix Inc. Matrix NC-138 is the first product in the Company's pipeline that was a result of the Company's R & D program stem cell and collagen growth. The Company does not anticipate filling orders until the last quarter of 2012.

On May 28, 2010, Proteonomix completed the development of a new formulation of Proteoderm. The new formulation will only be available at licensed health professionals' offices. The new product, Proteoderm PS (physician strength) is designed to provide a specific dosage of the active ingredient Matrix NC-138, to the patient depending on the patient's skin type and genomic analysis.

This should enable the professional to emphasize the use of information about an individual patient to select or optimize that patient's preventative and therapeutic care for their skin.

On June 1, 2010 Proteonomix retained Wolfe Axelrod Weinberger Associates (“WAW”), an investor relations agency for one year. WAW is to receive $7,500 a month and options to purchase 75,000 shares at a purchase price of $5.00 per share, which vest ratably over the 12 month contract commencing July 1, 2010. The Company has a right to terminate the agreement after three months including all fees and stock options. The maximum stock options to be issued, if terminated, would be 18,750 shares. The Company has expensed $30,000 through December 31, 2010, and issued 10,000 shares of stock in October 2010 to cover 2 additional months of service through November 30, 2010. The Company has not utilized the services subsequent to November 30, 2010 and terminated this agreement at that time. There is currently $15,000 due to Wolfe, Axelrod and Weinberger as of March 31, 2011. The Company has expensed in stock-based compensation 37,500 options at a value of $72,507.

On June 15, 2010 Proteonomix retained Logoform AG, to provide marketing, investor relations and capital raising services for Proteonomix for three months. Logoform AG received 100,000 stock options @ $5.00 per share exercisable until June 15, 2011, ratably over twelve months commencing July 15, 2010. The Company has expensed 49,998 options through December 31, 2010 as stock-based compensation in accordance with the terms of the agreement. There will be no additional options granted subsequent to December 31, 2010 as the contract has been terminated. The value of the options was $96,673 for the year ended December 31, 2010 relating to these options. Logoform AG also received 50,000 shares of Proteonomix freely tradable, duly authorized and validly issued shares to be paid by a third party on behalf of the Company. Logoform AG will also receive a four percent finder’s fee for equity or debt raised up to $3,000,000.

On June 16, 2010 Proteonomix shares began to trade on the OTC Bulletin Board under the symbol PROT.

On January 3, 2011 Ian McNiece joined our Board of Directors.

On January 3, 2011 the Company formed a new subsidiary, THOR BioPharma, Inc., in order to provide an entry into the pharmaceutical market. On March 2, 2011, The Company entered into an agreement with The Cohen McNiece Foundation, Inc. (the "Foundation"), a Florida not-for-profit corporation, to exclusively develop and license the Foundation's UMK-121 Mobilization of Bone marrow Stem Cell technology ("UMK-121") which is a proprietary technology based upon existing FDA approved drugs. The License imposes no upfront costs on the Issuer which will sublicense UMK-121 to its wholly owned subsidiary THOR BioPharma. The Issuer is required to make milestone payments to the Foundation upon 1) the issuance of a patent, 2) completion of Phase III trials and 3) commercialization which will require the payment of a 3% royalty on net sales. On April 7, 2011, the Company announced that it filed a provisional patent application in anticipation of commencement of its initial clinical trial of a drug combination thought to extend life expectancy for a class of terminally ill patients awaiting liver transplants. The Company, based upon its exclusive license agreement to develop Mobilization of Bone Marrow Stem Cells Technology (UMK-121), filed a patent application in April 2011, covering mobilization of non-hematopoietic stem cells for applications in regenerative medicine.

On June 16, 2011, the Company announced that it had engaged the services of Bedminster Financial Group, Ltd. to provide investment banking services for the Company with a view to finding joint venture partners and/or strategic investments into one or more of its subsidiaries in order to advance the scientific and commercial development of the subsidiaries and the technologies possessed by the subsidiaries.

On September 6, 2011, the Company announced that Michael Cohen, Chief Executive Officer of Proteonomix and Ian McNiece, the Company’s Chief Scientific Officer had met with the team at Gilford Securities, the Company’s Investment Banker at that time, and Aegis Capital. Mr. Cohen and Dr. McNiece updated them on the development of the Company’s technology and the Company’s technical position in several different areas of research and development.

On October 17, 2011, the Company announced that it has decided to examine the possibility of licensing its stem cell diabetes related technology to another company in light of continued progress toward its trial of UMK-121, its stem cell treatment for patients awaiting liver transplant to overcome End Stage Liver Disease.

On October 19, 2011, the Company announced that it intends to move forward with the testing of its StromaCel technology through its PRTMI subsidiary or its affiliates. The Company decided to examine the possibility of testing its cardiac stem cell treatment offshore in light of the progress toward its trial of UMK-121, its stem cell treatment for patients awaiting liver transplant to overcome End Stage Liver Disease, in the United States.

On November 15, 2011, the Company entered into an agreement with the University of Miami, to conduct a FDA human clinical trial, in patients afflicted with End Stage Liver Disease, of the Issuer’s UMK-121 Biopharmaceutical Stem Cell Technology which is a proprietary technology based upon existing FDA approved drugs. The Company sublicensed UMK-121 to its wholly owned subsidiary THOR BioPharma. The Company is required to pay $105,000 to the University and the University will absorb all other costs associated with the study. The Company has agreed to pay a 3% net royalty to the Foundation in the event of commercialization of UMK-121. On December 27, 2011, the Company announced that it had completed payment of the $105,000 to the University.

This trial was to commence in the first quarter of 2012. On April 10, 2012, the University of Miami terminated the Research Agreement between the University and the Company by delivering written notice of the termination to the Company. The $105,000 that was paid by the Company was returned. The Company is currently interviewing other institutions to conduct this trial. The Company believes that the technology has applications in treating kidney, cardiac and lung diseases as well although very little work has been done in those areas.

Financial Operations Overview

Revenues

Our revenues and associated direct costs since inception ~~are~~were a result of our sales of donor sperm samples from our Sperm Bank of New York subsidiary, a company engaged in reproductive tissue banking. In ~~2012~~his wesubsidiary ~~anticipate~~was ~~the~~sold ~~beginning~~in ofApril ~~sales~~2012. We anticipate that later in ~~the~~2012 ~~last~~we ~~quarter~~will ~~for~~commence sales of our Proteoderm products.

General and Administrative Expenses

General and administrative expenses consist primarily of the costs associated with our general management, including salaries, professional fees such as legal and accounting, marketing expenses and advisory fees. We have increased our general and administrative expense for legal and accounting compliance costs, investor relations and other activities associated with operating as a publicly traded company. We have strengthened our administrative capabilities through various consulting agreements. Continued increases will also likely result from additional operational, financial, accounting and advisory contracts. ~~The majority of our expenses were paid by stock based compensation agreements.~~

Income Taxes

We have not recognized any deferred tax assets or liabilities in our financial statements since we cannot assure their future realization. Because realization of deferred tax assets is dependent upon future earnings, a full valuation allowance has been recorded on the net deferred tax assets, which relate primarily to net operating loss carry-forwards. In the event that we become profitable within the next several years, we have net deferred tax assets (before a 100% valuation allowance) of approximately $7,~~025~~377,~~932~~228 that may be utilized prior to us having to recognize any income tax expense or make payments to the taxing authorities. Utilization of our net operating loss carry-forwards in any one year may be limited under IRC Section 382, and we could be subject to the alternative minimum tax, thereby potentially diminishing the value to us of this tax asset.

Principal Offices

The Company leases approximately 3,269 square feet of office space pursuant to the terms of a lease entered into on April 13, 2010, which expired on April 30, 2011, for a monthly lease payment of $5,585. The Company renewed the agreement on a month to month basis until January 31, 2012 when it abandoned that lease and took temporary office space in the offices of one of its directors and General Counsel, Roger Fidler. The Company believes that such office space will be sufficient for its needs until it leases new office space in the North New Jersey area. The Company’s principal offices are thus now located at 145 Highview Terrace, Hawthorne, NJ 07506. Our telephone number at such address is (~~855~~973) ~~467~~949-~~7682~~4195. The use of this space is at will and the Company pays $500 a month for the space amounting to approximately 500 square feet.

Results of Operations (Continuing and Discontinued)

~~Three~~Six Months Ended ~~March~~June 3130, 2012 Compared to the ~~Three~~Six Months Ended ~~March~~June 3130, 2011

~~The~~Operating ~~following~~segment ~~analysis~~data ~~reflects~~for the ~~condensed~~six ~~consolidated~~months ~~results~~ended ofJune ~~operations of Proteonomix~~30, ~~Inc.~~2012 ~~and~~is ~~its~~as ~~subsidiaries.~~follows:

2012	Stem-Cell/Thor	Proteoderm		Sperm Bank	PRTMI & PRTMI RD(1)	StromaCel/ XGen		Total
	Stem-Cell/Thor	Proteoderm	Sperm Bank (Discontinued)	PRTMI & PRTMI RD(1)	StromaCel/ XGen		Total
Sales	$ -	$ -	$2,290	$~~2,290~~ -	$ -	$-	$2,290	~~$2,290~~
Cost of sales	$ -	$ -	$585	$~~585~~ -	$ -	~~$ -~~	$585	~~$585~~
Gross profit	$ -	$ -		$1,705	$ -	$ -		$1,705
Gross profit (loss)	$ -	$ -	$1,705	$ -	$ -		$1,705
Operating expenses	$2,~~124~~976,~~303~~536	$-	$-	$-	~~$ -~~	$-	$2,976,536	~~$2,124,303~~
Depreciation and amortization	$918,~~535~~955	$ -	$ -	$ -	$ -	~~$ 85,047~~	$18,955	~~$94,582~~
Other income (expense)	$263,~~395~~147,931	~~($925)~~	$ -	~~$ -~~	~~($37)~~	~~($446)~~	$3,147,931	~~$24,987~~
Net income (loss)	$(23,~~107,443)~~04579	($~~925~~1,850)	$51,678	($~~1,705~~75)	($37170,810)	~~($85,493)~~	($183,523)	~~($2,192,193)~~
(1) PRTMI RD is a wholly-owned subsidiary of PRTMI.
Segment assets	$2,928,079	$201,500	$-	$-	$2,624,675		$5,754,254
2011	Stem-Cell	Proteoderm		Sperm Bank	PRTMI & PRTMI RD(1)	StromaCel/ XGen		Total
Fixed Assets, net of depreciation	$31,885	$ -	$ -	$ -	$ -		$31,885
Sales	$ -	$ -		$8,165	$ -	$-		$8,165
Cost of sales	$ -	$ -		$3,379	$ -	$ -		$3,379
Gross profit	$ -	$ -		$4,786	$ -	$ -		$4,786
Operating expenses	$170,938	$-		$20,094	$ -	$-		$191,032
Depreciation and amortization	$8,858	$ -		$ -	$ -	$ 85,047		$93,905
Other income (expense)	($17,980)	($914)		$ -	($37)	($442)		($19,373)
Net income (loss)	$(197,776)	($914)		($15,308)	($37)	($86,489)		($299,524)
(1) PRTMI RD is a wholly-owned subsidiary of PRTMI.

~~Net~~PRTMI ~~Revenues. Net~~RD ~~revenues~~is ~~were $1,705 for the three month period ended March 31, 2012, compared to $8,165 for the comparable period in 2011, or~~ a ~~decrease~~wholly-owned subsidiary of ~~$6,460~~PRTMI. ~~The decrease is due to no income received for storage fees as the Company no longer charges this component as the Company winds down this segment.~~

Cost of Sales. Cost of sales for the three months ended March 31, 2012 was $585, compared to $3,379 during the same period in 2011, a decrease of $2,794. The decreased costs are the result of no activity in the quarter ended March 31, 2012 as the Company winds down operations of the sperm bank services.



2011	Stem-Cell	Proteoderm	Sperm Bank	PRTMI & PRTMI RD(1)	StromaCel/ XGen	Total
Sales	$ -	$ -	$11,979	$ -	$-	$11,979
Cost of sales	$ -	$ -	$7,161	$ -	$ -	$7,161
Gross profit	$ -	$ -	$4,818	$ -	$ -	$4,818
Operating expenses	$312,262	$-	$388,087	$ -	$170,095	$520,444
Depreciation and amortization	$19,189	$ -	$ -	$ -	$ -	$19,189
Other income (expense)	($36,053)	($1,840)	$ -	($74)	($888)	($38,855)
Net income (loss)	$(367,054)	($1,840)	($33,269)	($74)	($170,983)	($573,670)
(1) PRTMI RD is a wholly-owned subsidiary of PRTMI.

	37

~~Operating~~Net ~~Expenses and Depreciation~~Revenues. ~~Operating~~Net ~~expenses~~revenues ~~and~~were ~~depreciation~~$1,705 for the ~~three~~six ~~months~~month period ended ~~March~~June 3130, 2012, ~~increased~~compared ~~$1,934,002 (678.9%)~~ to $211,~~218,885~~979 for ~~2012~~the ascomparable ~~compared~~period toin ~~$284~~2011,~~883~~ ~~for~~or ~~the~~a ~~same~~decrease ~~period~~of ~~in 2011~~$10,274. The ~~table~~decrease ~~below~~is ~~details~~due ~~the~~to ~~components~~no ofincome ~~operating~~received ~~expense,~~for asstorage ~~well~~fees as the ~~dollar~~Company ~~and~~no ~~percentage~~longer ~~changes~~charges ~~for~~this component as the ~~three-month~~Company ~~period~~winds ~~ended~~down ~~March~~this 31segment. The segment was sold in April 2012 and is part of discontinued operations.

34Cost of Sales. Cost of sales for the six months ended June 30, 2012 was $585, compared to $7,161 during the same period in 2011, a decrease of $6,576. The decreased costs are the result of no activity for the six months ended June 30, 2012 as the Company winds down operations of the sperm bank services. The segment was sold in April 2012 and is part of discontinued operations.

~~Three~~Operating ~~Months~~Expenses ~~Ended~~and ~~March~~Depreciation. Operating 31expenses and depreciation for the six months ended June 30, 2012, increased $2,479,876 (459.6%) to $3,019,455 for 2012 as compared to $539,579 for the same period in 2011. The table below details the components of operating expense, as well as the dollar and percentage changes for the six-month period ended June 30.

2012


Wage and wage related costs	$ 268,985	$ 131,354	$ 137,631	104.8
Professional consulting and marketing fees	2,297,020	65,237	2,231,783	3,421.0
Research and development	257,666	209,695	47,971	22.9
Insurance costs	8,479	3,885	4,594	118.2
Rent - building and equipment	2,500	18,195	(15,695)	(86.3)
Travel and related	-	14,394	(14,394)	(100.0)
Miscellaneous expenses	122,931	39,505	83,426	211.2
Depreciation and amortization	18,955	19,189	(234)	(1.2)
Total	$ 2,976,536	$ 501,454	$ 2,475,082	493.6

~~2011~~ Wage and wage related costs, which includes salaries, commissions, taxes and benefits, increased $137,631 ~~Change~~ (44.2%), ~~Change~~due to an increase in wages and wage related expenses as the Company increased personnel as a result of the private placement.

~~Wage~~Professional fees include legal, accounting, stock transfer agent, SEC filing, and ~~wage~~general ~~related~~consulting ~~costs~~ fees. Professional fees increased for the six months ended June 30, 2012 versus the same period last year by $ 952,~~279~~ 231,783 due to: an increase of $ 66238,~~079~~ 650 in common shares issued for services rendered, and for professional fees related to the private placement in the three months ended March 31, 2012 which includes fees earned by the placement agent of $ 29267,~~192 44~~249 in cash paid out of closing, and $1,293,509 in value of the Series E Preferred Stock Warrant.2

~~Professional~~Research and development costs represent costs related to developing the Company’s technology. These costs include consulting fees, license fees, travel costs and amortization of the license fees. These costs increased $47,971 in the six months ended June 30, 2012 from $209,695 in 2011 to $257,666 in 2012.

1Insurance costs in the six months ended June 30,~~997~~ 2012,~~005 79~~ were $8,~~779 1~~479 compared to $3,~~917~~885 for the same period in 2011,~~226 2~~ an increase of $4,~~403~~594 (118.2%). The increase is attributed to the increase in policy limitations and the policy for D & O insurance. This policy was renewed in April 2012.

~~Insurance~~Rent costs - 1decreased by $15,~~458~~ 695 (~~1,458) (100~~86.03%) to $2,500 in the six months ended June 30, 2012, as compared to $18,195 for the same period in 2011, due to the Company’s relocation of their corporate offices and the ceasing of rent associated with their sperm bank operations.

~~Rent~~Travel –expense ~~building~~for ~~and~~the ~~equipment - 4~~six months ended June 30,~~882 (4~~ 2012 of $0 compared to the same period for 2011 of $14,~~882)~~ 394, or a decrease of $14,394 (100.0%). The decrease in travel is related to all of the travel costs in 2012 related to research and development activities.

~~Travel~~Miscellaneous ~~and~~expense ~~related 16~~increased by $57,~~782 11~~840 to $133,~~487 5~~910 for the six months ended June 30,~~295 46~~ 2012, as compared to $76,070 for the same period in 2011.1 The increase was due to the Company’s private placement which enabled them to ramp up development again.

~~Miscellaneous~~Depreciation expense in our operating expenses 15 for the six months ended June 30,~~237 27~~ 2012 of $18,~~285 (12~~955 compared to the same period for 2011 of $19,~~048) (44~~189 decreased marginally as a result of the completion of the depreciation of certain depreciable assets.2)

Depreciation and amortization 94,582 93,905 677 0.738

Stock based compensation - - - 100.0

----------------- ------------------- ------------------- ----------------

Total

$ 2,218,885 $ 284,883 $ 1,934,002 678.9

Wage and wage related costs, which includes salaries, commissions, taxes and benefits, increased $29,192 (44.2%), due to an increase in wages and wage related expenses as the Company increased personnel as a result of the private placement.

Professional fees include legal, accounting, stock transfer agent, SEC filing, and general consulting fees. Professional fees increased for the three months ended March 31, 2012 versus the same period last year by $1,917,226 (2,403.2%) due to: an increase of $224,900 in common shares issued for services rendered, and for professional fees related to the private placement in the three months ended March 31, 2012 which includes fees earned by the placement agent of $267,249 in cash paid out of closing, and $1,293,509 in value of the Series E Preferred Stock Warrant.

Insurance costs in the three months ended March 31, 2012, were $0 compared to $1,458 for the same period in 2011, a decrease of $1,458 (100%). The decrease is attributed to a reduction in policy limitations and the policy for D & O insurance expiring. This policy was renewed in April 2012.

Rent decreased by $4,882 (100%) to $0 in the three months ended March 31, 2012, as compared to $4,882 for the same period in 2011, due to the Company’s relocation of their corporate offices and the ceasing of rent associated with their sperm bank operations.

Travel expense for the three months ended March 31, 2012 of $16,782 compared to the same period for 2011 of $11,487, or an increase of $5,295 (46.1%). The increase in travel related to meetings in Miami to finalize certain contracts.

Miscellaneous expense decreased by $12,048 (44.2%) to $15,237 for the three months ended March 31, 2012, as compared to $27,285 for the same period in 2011. The decrease was due to the Company’s lack of cash flow until private placement occurred in early March 2012.

Depreciation expense in our operating expenses for the three months ended March 31, 2012 of $94,582 compared to the same period for 2011 of $93,905 increased as a result of the amortization of the license and the patents.

Stock-based compensation, which represents a noncash expense category, represents stock-based compensation to consultants under various contracts. During the three months ended March 31, 2012 and 2011, the Company recognized $0 and $0 in stock-based compensation expense for consultants.

The Company measures employee stock option expense in based on the Black-Scholes fair value as outlined above in accordance with ASC 718-10. ASC 718-10 requires the recognition of all share-based payments to employees or to non-employee directors, as compensation for service on the Board of Directors, as compensation expense in the consolidated financial statements. The amount of compensation is measured based on the estimated fair values of such stock-based payments on their grant dates, and is amortized over the estimated service period to vesting. Consulting expense for stock-based payments to consultants is based on the fair value of the stock-based compensation at inception and amortized over the estimated service period but, in accordance with ASC 505-50, is remeasured on each reporting date until the performance commitment is complete.

35Other Income (Expense). Other income (expense) includes interest income, interest expense and other non-operating income. Other income for the six months ended June 30, 2012 was $3,147,931 compared to other expense of $38,855 for the same period last year. The increase in other income from 2011 of $3,109,076 is mostly the result of the forgiveness of payables related to the settlement of certain payables aggregating $838,581, which includes $12,129 in the gain on disposition of SBNY, interest income of $32,802 recognition of an adjustment for the fair value of derivative liability of $2,342,152.

~~Other~~Net ~~Income~~Loss ~~(Expense).~~and ~~Other~~Net Loss per Share. Net income for ~~(expense)~~the ~~includes~~six ~~interest~~months ~~income~~ended June 30, ~~interest~~2012 ~~expense~~was ~~and~~$183,524, ~~other~~compared ~~non-operating~~to ~~income~~a loss of $573,670 for the same period in 2011, for an reduction in net loss of $757,194. ~~Other~~Net ~~income~~profit per share for the ~~three~~six months ended ~~March~~June 3130, 2012 was $~~24,987~~0.02 compared to ~~other~~a ~~expense~~loss ofper share of $~~19,373~~0.10 ~~for~~in the same period ~~last~~for ~~year~~2011, based on the weighted average shares outstanding of 7,846,957 and 5,832,592, respectively. The ~~increase~~increased net profit for the six months ended June 30, 2012 compared to the same period in ~~other~~2011 ~~income~~arose from ~~2011~~the following: (i) decreased net revenue of $4410,~~360~~274, is(ii) ~~the~~decreased ~~result~~cost of ~~the~~sales ~~forgiveness~~of $6,576, (iii) increased salary and benefit costs of ~~payables~~$47,971, ~~related~~(iv) toincreased ~~the~~professional ~~settlement~~fees of $2,231,783, (v) an increase in research and development costs of $47,971, (vi) an increase in insurance costs of $4,594, (vii) decreased travel and entertainment costs of $14,394, (viii) an increase in miscellaneous costs of $19,616, (ix) a ~~claim~~decrease ~~for~~in ~~legal~~rent ~~services~~expense of $4315,~~812.~~695, (x) decreased depreciation expense of $234, and (xi) an increase in other net non-operating income of $271,946.

~~Net Loss and Net Loss per Share~~. Net loss for the three months ended March 31, 2012 was $2,192,193, compared to $299,524 for the same period in 2011, for an increased net loss of $1,892,669. Net loss per share for the three months ended March 31, 2012 was $0.28 compared to $0.06 in the same period for 2011, based on the weighted average shares outstanding of 7,805,886 and 5,365,706, respectively. The increased net loss for the first quarter of 2012 compared to the same period in 2011 arose from the following: (i) decreased net revenue of $6,460, (ii) decreased cost of sales of $2,794, (iii) increased salary and benefit costs of $29,192, (iv) increased professional fees of $1,917,226, (v) a decrease in insurance costs of $1,458, (vi) increased travel and entertainment costs of $5,295, (vii) a decrease in miscellaneous costs of $12,048, (viii) a decrease in rent expense of $4,882, (ix) increased depreciation expense of $677, and (x) an increase in other net non-operating income of $44,360.

LIQUIDITY AND CAPITAL RESOURCES

The following table presents a summary of our net cash provided by (used in) operating, investing and financing activities and discontinued operations:

	Three Months Ended March 31
	Six Months Ended June 30
Category	2012	2011
Net cash provided (used) in operating activities	$ (~~503~~1,~~207~~065,506)	$ ~~(26~~168,~~552)~~676
Net cash provided (used) in investing activities	(14,717)	(9,560)
Net cash (used) in investing activities	(49,204)	(9,560)
Net cash provided by financing activities	3,~~717~~511,~~366~~349	3782,~~019~~233
Net increase (decrease) in cash	$ 3,199,442	$ 907
Discontinued operations	1,705	(240,853)
Net increase (decrease) in cash	$ 2,398,344	$ 496

Net Cash Used in Operations

Net cash used in operating activities for the ~~three~~six months ended ~~March~~June 3130, 2012, was $~~503~~1,~~207~~065,506, compared with net cash ~~used~~provided inby operating activities of $26168,~~552~~676 during the same period for 2011, or an increase in the use of cash for operating activities of $~~476~~896,~~655~~830. The decrease in the use of cash is due to: (i) increased net (loss) from continuing operations of $1399,~~892,669~~588 offset by the value of the preferred stock warrants issued to the placement agent of $1,293,509, a decrease in prepaid expenses of $~~122~~293,000 and a decrease in accounts payable of $~~268~~1,~~943~~048,998.

Net Cash Used in Investing Activities

In 2012 and 2011, the only investing activities were the increase in costs associated with filing patents of $1436,~~717~~569 and $9,560, respectively, and the acquisition of equipment in 2012 of $12,635.

Net Cash Provided by Financing Activities

Net proceeds from financing activities were $3,~~717~~511,~~366~~349 for the ~~three~~six months ended ~~March~~June 3130, 2012 compared with $3782,~~019~~233 for the same period in 2011, or an increase of $3,~~680~~429,~~347~~116. Of the 2012 proceeds from financing activities, the majority was from the private placement funding from the investors in the SPA. The private placement enabled the Company to commence moving forward with their development of their patented technology and pay down a portion of their liabilities. In 2011, 100% was from the issuance of new debt to related parties from cash infused into the Company. Management is seeking, and expects to continue to seek to raise additional capital through equity or debt financings, including through one or more equity or debt financings to continue their development. However, there can be no assurance that the Company will be able to raise such additional equity or debt financing or obtain such bank borrowings on terms satisfactory to the Company or at all.

Cash and Cash Equivalents

Our cash and cash equivalents increased during the ~~three~~six months ended ~~March~~June 3130, 2012 by $32,~~199~~398,~~442~~344, compared to an increase in cash and cash equivalents during the same period in 2011 of $~~907~~496. AsThe ~~outlined above, the~~ increase in cash and cash equivalents ~~for~~includes ~~the~~$2,275 ~~current~~and ~~fiscal period was the result of;~~ (i$240,853) anrelated ~~increase~~to inthe ~~cash~~change ~~used~~ in ~~operating activities of $209,406, (ii) an increase in~~ cash ~~used~~from ~~for~~discontinued ~~investing activities of $272~~operations,~~406,~~ ~~and~~which ~~(iii)~~were anall ~~increase~~operating ~~in cash provided by financing~~ activities ~~of $3,680,347~~.

Working Capital Information - The following table presents a summary of our working capital at the end of each period:

	(Unaudited)
Category	~~March~~June 3130, 2012	December 31, 2011
Cash and cash equivalents	$ 3,199,455	$ 13
Cash and cash equivalents (continuing operations)	$ 2,398,357	$ -
Current assets	32,~~967~~783,~~123~~357	230,266
Current liabilities	65,~~641~~755,~~346~~340	7,038,600
Working capital (deficit)	$ (2,~~674~~971,~~223~~983)	$ (6,808,334)

At ~~March~~June 3130, 2012, we had a working capital deficit of $2,~~674~~971,~~223~~983, compared with a working capital deficit at December 31, 2011 of $6,808,334, a decrease in working capital deficit of $43,~~134~~836,~~111~~351. As of ~~March~~June 3130, 2012, the Company had cash and cash equivalents of $32,~~199~~398,~~455~~357 as compared to $130 on December 31, 2011 (from continuing operations). The increase in cash is the net result of our operating, investing and financing activities outlined above. ~~Our~~Effective April 1, 2012 our revenue generating activities ~~during~~and ~~the~~only ~~period,~~operating assubsidiary inwas ~~previous~~sold. ~~years,~~This ~~have~~subsidiary had not produced sufficient funds for profitable operations, and we have incurred operating losses since inception. Accordingly, we have continued to utilize the cash raised in our financing activities to fund our operations. In addition to raising cash through additional financing activities, we may supplement our future working capital needs through the extension of trade payables, although we have repaid some of these, and we have had increases in accrued expenses, most notably payroll to our management. We have started paying management as they have ramped up their efforts in the development of our core technology as a result of the financing that occurred in March 2012. In view of these matters, realization of certain of the assets in the accompanying balance sheet is dependent upon

our continued operations, which in turn is dependent upon our ability to meet our financial requirements, raise additional financing, and the success of our future operations.

In view of the above matters, realization of certain of the assets in the accompanying balance sheets is dependent upon our continued operation, which in turn is dependent upon our ability to meet our financial requirements, raise additional financing, and the success of its future operations.

In addition, we have commenced the development stage as of April 1, 2012 as we have no revenue producing activities, as we enter the clinical trials. We anticipate that revenues will be generated by our Proteoderm products in 2012.

Additional Capital

To the extent that additional capital is raised through the sale of our equity or equity-related securities of our subsidiaries, the issuance of our securities could result in dilution to our stockholders. No assurance can be given that we will have access to the capital markets in the future, or that financing will be available on terms acceptable to satisfy our cash requirements, implement our business strategies, If we are unable to access the capital markets or obtain acceptable financing, our results of operations and financial condition could be materially and adversely affected. We may be required to raise substantial additional funds through other means. We have not begun to receive revenues from our cord blood services or cosmeceutical sales at this point. Management may seek to raise additional capital in addition to the private placement completed in March 2012 through one or more equity or debt financings or through bank borrowings. We cannot assure our stockholders that our technology and products will be commercially accepted or that revenues will be sufficient to fund our operations.

Off-Balance Sheet Arrangements

We do not maintain any off-balance sheet arrangements, transactions, obligations or other relationships with unconsolidated entities that would be expected to have a material current of future effect upon our financial condition or results of operations as of ~~March~~June 3130, 2012 and December 31, 2011.

Financial Condition, Going Concern Uncertainties and Events of Default

During the ~~three~~six months ended ~~March~~June 3130, 2012, Proteonomix’ entered the development stage, and prior to that the revenue generating activities ~~have~~had not produced sufficient funds for profitable operations and we have incurred operating losses since inception. In view of these matters, realization of certain of the assets in the Company’s consolidated balance sheet is dependent upon continued operations, which in turn is dependent upon our ability to meet our financial requirements, raise additional financing on acceptable terms, and the success of future operations. Also, we have outstanding trade and accrued payables of $32,~~212~~127,~~409~~378 including accrued salaries due to our management of $1,~~701~~732,~~667~~500. Also, our Senior Officer’s net outstanding loans were $~~692~~599,~~931~~164. The Company did close on a private placement during March 2012, which netted them approximately $3,500,000. These funds will be utilized in the continuance of the development of the Company’s technology and repay certain long outstanding payables.

Significant Accounting Policies

The preparation of the Company’s financial statements requires management to make estimates, judgments, and assumptions that affect the reported amounts of assets, liabilities, revenues and expenses during the periods presented. For a discussion of the Company’s critical accounting policies and estimates, refer to “Management’s Discussion and Analysis of Financial Condition and Results of Operations” in the Company’s Annual Report on Form 10-K for the year ended December 31, 2011. Except as disclosed in Note 2 of our 2011 Form 10-K, there have been no material changes to these critical accounting policies that impacted the Company’s reported amounts of assets, liabilities, revenues or expenses during the ~~three~~six month period ended ~~March~~June 3130, 2012.

ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISKS

We have not entered into, and do not expect to enter into, financial instruments for trading or hedging purposes.

ITEM 4. CONTROLS AND PROCEDURES

Evaluation of Disclosure Controls and Procedures

Management of Proteonomix Inc., which consists primarily of our CEO and CFO, is responsible for establishing and maintaining adequate internal control over financial reporting (as defined in Rule 13a-15(f) under the Exchange Act). The Company’s internal control over financial reporting has been designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles generally accepted in the United States of America.

The Company’s internal control over financial reporting includes policies and procedures that pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect transactions and dispositions of assets of the Company; provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with accounting principles generally accepted in the United States of America, and that receipts and expenditures are being made only in accordance with authorization of management and directors of the Company; and provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use or disposition of the Company’s assets that could have a material effect on the Company’s financial statements.

Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Therefore, even those systems determined to be effective can provide only reasonable assurance with respect to financial statement preparation and presentation. Projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.

Management assessed the effectiveness of the Company’s internal control over financial reporting at March 31, 2012. In making this assessment, management used the criteria set forth by the Committee of Sponsoring Organizations of the Treadway Commission (“COSO”) in Internal Control—Integrated Framework. During our assessment of the effectiveness of internal control over financial reporting as of March 31, 2012, management identified significant deficiencies related to (i) the absence of U.S. GAAP expertise or an internal accounting staff until April 2012, (ii) our internal audit functions and (iii) the absence of an Audit Committee which resulted in an ineffective system of internal control at March 31, 2012. 35

~~Based~~Management onassessed ~~our~~the ~~evaluation~~effectiveness ~~under~~of the ~~frameworks~~Company’s ~~described~~internal ~~above~~control over financial reporting at June 30, ~~our~~2012. In making this assessment, management ~~has~~used ~~concluded~~the ~~that~~criteria set forth by the Committee of Sponsoring Organizations of the Treadway Commission (“COSO”) in Internal Control—Integrated Framework. During our assessment of the effectiveness of internal control over financial reporting ~~was~~as ~~not~~of ~~effective~~June as30, 2012, management identified significant deficiencies related to (i) the absence of ~~March~~U.S. 31GAAP expertise or an internal accounting staff until April 2012, (ii) our internal audit functions and (iii) the absence of an Audit Committee which resulted in an ineffective system of internal control at June 30, 2012.

Based on our evaluation under the frameworks described above, our management has concluded that our internal control over financial reporting was not effective as of June 30, 2012.

In order to correct the above mentioned deficiencies, we have taken and plan on taking the following remediation measures:

We intend to appoint additional members to our board of directors in 2012 and establish an audit committee.

We have hired additional staff in 2012 familiar with financial reporting controls and compliance with Sarbanes-Oxley rules and regulations as well as U.S. GAAP however as of ~~March~~June 3130, 2012, no changes have occurred.

We intend to hire internal audit staff to consolidate and concentrate our efforts with the building of its six subsidiaries.

We intend to segregate duties and implement appropriate review procedures throughout the accounting and administration controls.

This quarterly report does not include an attestation report of the Company’s registered public accounting firm regarding internal control over financial reporting. Management’s report was not subject to attestation by the Company’s registered public accounting firm pursuant to temporary rules of the Securities and Exchange Commission that permit the Company to provide only Management’s report in this quarterly report.

Changes in Internal Controls

There were no changes in the Company’s internal controls over financial reporting during the period covered by the Report that have materially affected, or are reasonably likely to materially affect, the Company’s internal controls over financial reporting.

PART II. OTHER INFORMATION

ITEM 1. LEGAL PROCEEDINGS

The Company has recently been sued by Wolf Axelrod for $38,000. The Company ~~intends~~settled ~~to vigorously defend~~ this action for $35,000. The Company has also been advised that John Hopkins University will seek to collect against National Stem Cell, Inc. on its $90,000 judgment. The Company ~~has~~settled ~~also~~this ~~been~~for ~~threatened~~$85,000 ~~with~~in ~~litigation~~June ~~by Fred Grant on a contract balance~~2012. ~~The Company intends to vigorously defend this action if brought.~~

On April 24, 2012, the Company was served with a subpoena from the United States Securities and Exchange Commission pursuant to a formal investigation “In the Matter of Proteonomix, Inc. HO-11836”.

A former law firm that has entered bankruptcy claims that the Company owes it approximately $200,000. The Company issettled ~~presently~~this ~~negotiating~~debt ~~with~~in ~~the~~June ~~Trustee regarding payment of the debt~~2012.

ITEM 1A. RISK FACTORS

An investment in our common stock involves a high degree of risk. You should carefully consider the risks described below and other information contained in this Report in deciding whether to invest in our common stock. Additional risks not presently known to us or which we currently consider immaterial may also adversely affect our company. If any of the following risks actually occur, our business, financial condition and operating results could be materially adversely affected. In such case, the trading price of our common stock could decline, and you could lose a part of your investment.

Risks Related to Our Company and Our Operations

We have a severe working capital deficit and, in addition to proceeds from financings, we continue to have outstanding loans from our chief executive officer and accrued salaries due to our executive officers and employees in order to indirectly fund operations.

As of ~~March~~June 3130, 2012, we had a working capital deficit of approximately $23,~~674~~192,~~223~~959. ~~During~~Effective ~~the~~April ~~three months ended March 31~~1, 2012, our revenue generating activities and only operating subsidiary was sold. This subsidiary had not produced sufficient funds for profitable operations, and we have incurred operating losses since inception. Accordingly, we have continued to utilize the cash raised in our financing activities to fund our operations. In addition to raising cash through additional financing activities, we may supplement our future working capital needs through the extension of trade payables, although we have repaid some of these, and we have had increases in accrued expenses, most notably payroll to our management. We have started paying management as they have ramped up their efforts in the development of our core technology as a result of the financing that occurred in March 2012. Although we have obtained cash from certain financings, we continue to have outstanding loans from our chief executive officer of approximately $~~629~~588,~~297~~797, and accrued salaries due our executive officers in the amount of $1,~~701~~732,~~667~~500. In the event we are unable to pay our accrued salaries, we may not be able to maintain them which could materially adversely affect our business and operations, including our ongoing activities.

ITEM 2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS

None

ITEM 3. DEFAULTS UPON SENIOR SECURITIES

None

ITEM 4. SUBMISSION OF MATTERS TO A VOTE OF SECURITY HOLDERS

None

ITEM 5. OTHER INFORMATION

None

ITEM 6. EXHIBITS

Copies of the following documents are included as exhibits to this report pursuant to Item 601 of Regulation S-K.

			Incorporated by Reference		Filed Herewith
Exhibit No. 10.57	Exhibit Description Agreement with Gilford Securities, Inc.		Form	Filing Date
Exhibit No.	Exhibit Description		Form	Filing Date
31.1		Certification Pursuant to Rule 13a-14(a) or 15d-14(a) of the Securities Exchange Act of 1934, As Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 (CEO)				X
10.67 31.1		McNiece License Agreement Certification Pursuant to Rule 13a-14(a) or 15d-14(a) of the Securities Exchange Act of 1934, As Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 (CEO)				X X
31.2		Certification Pursuant to Rule 13a-14(a) or 15d-14(a) of the Securities Exchange Act of 1934, As Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 (CFO)				X
32.1		Certification Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 (CEO)				X
32.2		Certification Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 (CFO)				X

101.INS		XBRL Instance Document.*
101.SCH		XBRL Taxonomy Extension Schema.*
101.CAL		XBRL Taxonomy Extension Calculation Linkbase.*
101.DEF		XBRL Taxonomy Extension Definition Linkbase.*
101.LAB		XBRL Taxonomy Extension Label Linkbase.*
101.PRE		XBRL Extension Presentation Linkbase.*

Attached as Exhibit 101 to this report are the following financial statements from the Company’s Quarterly Report on Form 10-Q for the quarter ended March 31, 2012 formatted in XBRL (eXtensible Business Reporting Language): (i) the Consolidated Balance Sheets for the period ended March 31, 2012 (Unaudited) and December 31, 2011 (ii) the Consolidated Statements of Operations (Unaudited) for the three months ended March 31, 2012 and September 30, 2011, (iii) the Consolidated Statements of Cash Flows for the three months ended March 31, 2012 and 2011, and (iv) related notes to these financial statements tagged as blocks of text. The XBRL-related information in Exhibit 101 to this Quarterly Report on Form 10-Q shall not be deemed “filed” or as part of a registration statement or prospectus for purposes of Sections 11 or 12 of the Securities Act of 1933, as amended and is not filed for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of those sections.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this Report to be signed on its behalf by the undersigned, thereunto duly authorized.

PROTEONOMIX, INC. By: /s/ Michael Cohen Michael Cohen Chief Executive Officer (Principal Executive Officer) By: /s/ ~~Michael~~Thomas ~~Cohen~~Monahan ~~Michael~~Thomas ~~Cohen~~Monahan Chief Financial Officer (Principal Financial and Accounting Officer)

Date: ~~June~~August 1321, 2012

4138

Filing Compare · PROTEONOMIX, INC.